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SUMMARY
This thesis describes the development of specific 
assays for two important anti-cancer agents which have 
been available for some time, methotrexate (MTX) 
introduced in 1 949 and doxorubicin (ADR) introduced in 
1969. Both of these drugs undergo significant Phase I 
metabOjlism and since such metabolites may be of 
pharmacological or toxicological significance the assays 
developed had to be capable of estimating these as well 
as the parent drugs. High performance liquid chromato­
graphy (HPLC) is an ideal technique for this purpose.
The assay developed for MTX and its metabolites 
employed a liquid/solid extraction which gave 
reproducibly high recoveries of MTX, its deglutamated 
metabolites and their 7-hydroxylated derivatives, 
followed by an HPLC procedure using an anionic ion- 
pairing agent in the eluant which gave excellent 
chromatographic efficiency and resolution. This resulted 
in a highly sensitive and specific assay for all the 
above components.
The assay was applicable to serum and urine and a 
modified method applicable to in vitro studies was also 
developed and used for analyses of cells both bacterial 
and human, and the culture media in which they were 
grown.
XV
Studies using clinical samples showed that the assay 
was sufficiently sensitive to measure MTX and its 
metabolites in plasma from patients treated with low-dose 
oral MTX for psoriasis. High-dose studies were carried 
out during following IV infusions of MTX in cancer 
patients. The results obtained gave rise to some new 
findings concerning MTX handling.
In low-dose, intra-individual MTX clearance was 
highly reproducible, but there was substantial inter­
subject variation in this and other pharmacokinetic 
parameters. In particular MTX bioavailability varied 
between 17 and 120%. The implications of this and the 
other variations in disposition are considered.
In the high-dose studies the kinetics were markedly 
different from the low-dose studies, most probably due to 
the presence of other drugs and the possibility of third 
spaces. Sequential high-dose studies showed that changes 
in the renal component of clearance was a major factor 
in accumulation of 7-hydroxy methotrexate (7-OHMTX). 
Clearances were calculated from both urinary data and 
plasma data and the results were found to be comparable,
A second potential metabolite DAMPA, which had been 
reported in plasma by Donehower (1979) was detected in 
some plasma samples following high-dose MTX therapy. The 
kinetics indicate that the most likely source of this is 
as an impurity in the infusion fluid rather than as a 
result of metabolism in man by hepatic bacterial
XVI
deglutamation. This product was not detected in vitro 
following incubation of either bacterial or human cell 
lines with MTX.
A third potential metabolite of MTX, 7-OHDAMPA, 
not previously described in man, was synthesised and 
characterised in vitro and some evidence obtained as to 
its presence in urine from patients with DAMPA present in 
plasma.
An HPLC assay for doxorubicin (ADR) was developed 
which was highly sensitive for ADR and its main Phase I 
metabolites. The HPLC assay employed a novel separation 
mechanism which was fully investigated and an explanation 
proposed. The assay proved suitable for the examination 
of clinical samples.
The effects of gastrointestinal bacteria and human 
cell lines were investigated and metabolism of these 
drugs in some cells was found, although the relevance 
of these findings to cell resistance remains to be 
ascertained.
Similar studies with ADR showed that bacterial 
cells metabolised the drug but not to any of the known 
metabolites. These studies indicate that the use of 
specific methods for measuring metabolites of anti-cancer 
drugs as well as the parent drug can lead to more 
information as regards the metabolism and disposition of 
these drugs than the non-specific tracer methods employed 
in many reference studies. It is suggested that the
XVll
application of these and similar methods to clinical 
studies in patients treated with chemotherapeutic agents 
may lead to more rational individual dosage regimes 
giving rise to increased efficiency and reduced toxicity.
CHAPTER 1
GENERAL INTRODUCTION
GENERAL INTRODUCTION
Cancer is a derangement of normal cell growth. The 
neoplastic cells, are less well differentiated than normal 
cells and are not subject to the usual control 
mechanisms; this results in proliferative growth. Such 
derangement of cell growth can occur in any type of cell 
from the highly specialised to the general. It is often 
said t^at tumour growth is the rapid growth of cells, in 
some instances e.g. melanoma this is true, but often 
growth occurs over a long period; it is the uncontrol­
lable nature of growth that characterises these diseases.
Tumours may be broadly characterised as benign and 
malignant, the former are characterised by slow growth 
and a lack of spread to other sites; malignancies are 
more vigorous and are very likely to distribute 
secondaries from the primary site. Despite the lack of 
differentiation tumours are capable of producing 
biologically active proteins that may have e.g. endocrine 
functions.
In the diagnosis and treating of cancers Clinical 
Chemists have concentrated on the measurements of 'tumour 
markers' which have been detected in the plasma or urine 
of patients with specific tumours and also derangements 
in metabolism especially those which lead to 
abnormalities of endocrine function. The majority of 
these are poor diagnostic tools but some may be used in
prognosis to monitor treatment. Examples are enzymes and 
various hormones which have been used as tumour markers 
( ; Buckman, 1982; Ruddon, 1982).
Cell Kinetics
All dividing cells follow the cell cycle which has 
four main phases (Greenwald and Goldstein, 19 73). These 
are :
1 Mitosis
Which consists of prophase in which the chromosome 
condenses and each chromosome splits into 2 chromatids, 
each of which contains half of the original DNA and half 
of newly synthesised DNA, metaphase in which the 
chromosomes separate and become aligned along micro- 
tubules which connect the 2 centrioles of the nucleus; 
anaphase in which the chromatids separate and telophase 
in which the nucleus and cells divide.
2. GAPi (Gi) phase
This phase is variable depending on cell type. Cells 
which are not rapidly dividing, e.g. normal liver cells, 
remain in G-] , Cellular growth (in size) occurs mainly in 
this phase.
3. S-phase
DNA synthesis takes place in S-phase. It has a 
relatively constant duration in mammalian cells (6-8 
hours).
4. GAP? (G?) phase
In this phase, like G-) , the undivided cells are 
quiescent for a fairly constant time. In mammalian cells 
the average is about 2 hours.
This is the cell cycle and the time taken for one 
cycle is called the generation time. The generation time 
for human marrow cells (the most rapidly dividing) is 
slightly less than 24 hours.
The Behaviour of Cancer Cells
Cancer cells differ from normal cells in three ways 
(Wood and Strauli, 1973). These are;
1. Uncontrolled growth.
2. Invasion
Metastatic formation of some of the following:
(a) Enzymatic or other lytic factors that break 
down normal tissues.
(b) Tissue pressure caused by tumour growth.
3. Spread
Tumour cells spread and form métastasés by 
moving via both the blood vessels and the 
lymphatic system.
Medical treatment of cancer in all its forms is 
usually by radiotherapy, chemotherapy or a combination of 
these. Few of these procedures are highly effective and 
there are many side-effects.
During the last 40 years a wide range of anti-cancer 
drugs have been developed each of which have known 
effects on the growth of malignant cells.
Drug Classification (Caiman, Smyth and Tattersall, 1980)
A rough classification of the anti-neoplastic drugs 
divides them into the following groups.
1. Cell cycle (non-specific)
These drugs kill malignant and normal cells at any 
stage in the cell cycle or when quiescent. An example is 
nitrogen mustard (y radiation works in the same way).
2. Cell cycle (phase-specific)
The major drugs in this class are thymidine, 
vinblastine, vincristine, methotrexate and cytosine 
arabinos i de. These drugs are toxic to cells in 
particular phases of the cell cycle.
3. Cell cycle (non phase-specific)
The drugs in this class are cyclophosphamide, 
actinomycin D and the nitrosoureas. These drugs are 
toxic to the cells during periods of growth in the cell 
cycle, but not when quiescent i.e. G-] and G 2 •
The Effect of Anti-Cancer Drugs
All of these drugs may be effective against one type 
of tumour but ineffective against others. Continuous and 
long term research is underway in order to select the 
most appropriate regimens. At present there are a few 
tumours for which chemotherapy has been shown to provide 
a cure, these include acute lymphocytic leukaemia in
children, Burkitt's lymphoma, choriocarcinoma in women, 
and Hodgkin's disease. Some tumours are highly sensitive 
to chemotherapy giving long remissions, examples are 
chronic lymphocytic leukaemia, lymphomas, ovarian 
carcinoma, testicular teratoma, some head and neck 
tumours and acute myeloid leukaemia.
A further group of tumours are sensitive to 
chemotherapy but have limited remission. These include 
osteogenic sarcoma, myeloma, gastric carcinoma, bladder 
tumours and prostatic carcinoma. Chemotherapy has not so 
far been shown to be effective against non-small cell 
bronchogenic carcinoma, carcinoma of the pancreas, 
colorectal carcinoma or melanoma.
The ideal drug for the treatment of any individual 
cancer is one which is capable of penetrating a tumour 
and eliminating all malignant cells. It should also be 
free of acute or chronic side-effects. It is a fact that 
none of the drugs fit these criteria.
The toxicity of the anti-cancer drugs is due to the 
fact that they exert their effect on normal as well as 
malignant cells. Drugs which are active against cells 
which are rapidly dividing in fast growing tumours are 
also active against normal tissues with a high rate of 
turnover e.g. gut and blood cells. As an example of the 
latter the toxicity of some anti-neoplastic drugs to the 
bone marrow is illustrated in Table 1 (Caiman, Smyth and 
Tattersall, 1980).
TABLE 1
Marrow Toxicity of some Anti-Cancer Drugs
Drug Ana emia Neutropenia Thrombocytopenia
Methotrexate + ++ -H-
Mercaptopurine + ++ ++
Fluorouracil + + +
Cytosine arabinoside + ++ ++
Cyclophosphamide + 4-4- +
Melphalan + ++ ++
Chlorambucil + + +
Cis-platinum ++ + +
BCNU/CCNU + + ++
Adriamycin + ++ ++
Act inomy cin + ++ 44-
Bleomycin ± ± ±
Vincristine ± ± ±
Vinblastine + -f-f +
Combined regimes of two or more anti-neoplastic 
drugs are used in the treatment of most tumours. Some of 
these combinations have been found to be highly 
effective, h o w e v e r , interaction occurs both between 
chemotherapeutic agents and with other drugs which may be 
co-prescribed. Some of the better known interactions 
have been described by Stuart and Stockley (1979).
Therapeutic drug monitoring is becoming increasingly 
used for studying the disposition of drugs in patients 
under treatment in order to avoid toxicity, and to study 
the disposition in patients in order to maximise effect 
(Richens and Marks, 1982).
Chemotherapeutic drugs seem to fit the criteria 
which determine whether a drug should be measured. These 
are;
1. The drugs require to be given at doses near or 
within the toxic range in order to be effective i.e. 
a low therapeutic index.
2. They are administered to patients who may have 
abnormal"metabolism distribution"(fluid compart­
ments) or excretion.
The majority of studies of the effectiveness and/or 
toxicity of chemotherapeutic drugs have been concerned 
only with dosage. Measurements of plasma concentrations 
of drugs are increasing in clinical trials, but it is 
true to say that only for methotrexate (MTX) has an
established protocol been developed which relates plasma 
concentrations to the need for treatment with leucovorin. 
One example of - this protocol states that leucovorin 
rescue should be initiated when, following high-dose 
therapy, the MTX plasma concentration exceeds 10"^M at 24 
hours, 10"6m  at 48 hours or 10"?M at 72 hours. The level 
of potentially toxic metabolites are not taken into 
account (Nirenberg et al, 1977).
Part of the reason why more drug monitoring is not 
performed during chemotherapy is the lack of rapid 
specific methods for determining the drugs themselves and 
their active metabolites. In addition many studies of 
chemotherapeutic drugs use either rad iotracer-label led 
drugs in order to study the disposition, in which case it 
is not possible to differentiate between drug and 
metabolite or use other non-specific methods e.g. total 
fluorescence.
There are few reported studies in which specific 
measurements of drug and metabolite levels have been made 
during treatment.
In the case of doxorubicin (ADR), there is as yet no 
directly agreed link between plasma drug concentrations 
and toxicity. Again studies on metabolite concentrations 
in patients are few.
The aim of this thesis was therefore the development 
of HPLC methods, which have the advantage of specificity, 
for the measurement of MTX and its metabolites and ADR 
and its metabolites, and to study the source of these 
metabolites and their kinetics in vivo.
CHAPTER 2
METHOTREXATE
INTRODUCTION
HISTORY
The folate analogue aminopterin, an inhibitor of 
the enzyme dihydrofolic acid reductase (DHFR), essential 
for the synthesis of DNA was first discovered and 
investigated by Farber et al (in 1948 ), who demonstrated 
the effectiveness of aminopterin in children suffering 
from acute leukaemia; 10 out of 16 children responded 
with a temporary remission. However aminopterin is highly 
toxic, and this led to a search for a less toxic 
analogue. Methotrexate (ame thopter in) was proposed by 
Farber in 1949.
Leucovorin (folinic acid) was prepared in 1950 and 
its biological and chemical properties were studied 
(Broquist, Stokstad and Jukes, 1950). Leucovorin was 
found also to act as a substrate for DHFR, by which it is 
converted to tetrahydrofolic acid (Figure 1), thus 
preventing and reversing the toxic effect produced by 
methotrexate (MTX) and aminopterin (Schoenbach, Greenspan 
and Closky, 1950),
STRUCTURE
The structures of MTX, folic acid, leucovorin and 
aminopterin are shown in Figure 2. Aminopterin (4-amino 
pteroylglutamic acid) differs from folic acid by an amino 
group replacing the hydroxyl group at the 4-position.
LU
g
Q
co
>
X
H (0
Ü-
<
Z
Q
Ol
Q
O
<
O
-J
UJco
güw
Q)
iSH
i
Q)
I
Q)+J
î
I
*WO
§■H
tjtO
m0
1
•HIS
I
s
ü
<
O
o
IL.
O
ce
o
>-
X
Û
<IL
X
Q
COOH
ÇH,
O 1|1 ÇHy
C — N — CH— COOH
Methotrexate 
Folic acid 
Leucovorin 
Aminopterin
NHj
OH
OH
NH.
R
CHO
C H 3
H
H
H
FIGURE 2 3Zhe structure of Methotrexate and its analogues
10
Methotrexate ( 4-amino 4-deoxy methylpteroylgltitamic
acid) differs from aminopterin by méthylation at the 0 
position.
Leucovorin (folinic acid) is formyltetrahydro- 
folic acid and differs from folic acid by an aldehyde 
group at position.
MECHANISM OF ACTION
Di^FR is the enzyme responsible for converting 
dihydrofolic acid to tetrahydrofolic acid (Figure 1). 
MTX, like aminopterin, inhibits the reaction by revers- 
ibly competing with dihydrofolic acid thus disrupting the 
folate cycle which produces the C^ fragments necessary 
for the production of both purine nucleotides and 
thymidylate and consequently DNA synthesis.
Leucovorin reverses the inhibitory effect of MTX 
since it is converted in vivo to 5-methyltetrahydrofolic 
acid and then to tetrahydrofolic acid (Figure 1) (Bleyer,
1978) thereby replacing the pool of Ci group donors. 
Since MTX and leucovorin compete for the enzyme 
(Burchenal and Babcock, 1951) the relative concentrations 
of MTX and leucovorin are important.
Thymidine has also been used as a rescue agent in 
patients treated with MTX since it is converted to 
thymidylate, the major pyrimidine precursor for DNA 
synthesis (see Figure 1). The supply of purine 
nucleotides is not completely removed during DHFR 
inhibition since these are also synthesised in bone
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marrow cells which utilise predominantly preformed 
purines derived from the liver (Schornagel et al, 1978), 
but there is no comparable scavenging system by which 
thymidylate can be converted directly to the nucleotide. 
CLINICAL ASPECTS OF METHOTREXATE
Methotrexate (MTX) is used in the treatment of a 
variety of malignancies. Low doses are effective in 
choriocarcinoma (Hertz, Lewis and Lipsett, 1961), acute 
lymphocytic leukaemia (Freeman, Wang and Sinks, 1977) and 
breast carcinoma (Yap et al, 1979).
In high dosage, the drug is effective against 
malignant lymphoma (Djerassi and Kim, 1976), osteogenic 
sarcoma (Jaffe et al, 1974; Jaffe et al, 1977), carcinoma 
of the head and neck (Khandekar and Wolff, 1977; Vogler 
at al , 1 979 ) and small cell carcinoma of the lung
(Djerassi et al, 1972; Pitman and Frei, 1977).
MTX is usually used in conjunction with other anti­
neoplastic drugs either concomitantly or sequentially, A 
review was published recently (Cancer Treatment Reports 1981 
Dosage
MTX was first used clinically for acute lymphocytic 
leukaemia at an oral dose of 1-5 mg/m^ per day.
In the early 1960's intermittent parenteral MTX at 
30 mg/m^ twice weekly was observed to be more effective 
for the treatment of childhood acute lymphocytic 
leukaemia (Selawry and James, 1965). Solid human tumours 
resistant to these doses were shown to respond in many
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instances to short infusions (about 4 hours) of higher 
doses in the range of 100-200 m g / m ^  (Djerassi, 1967). 
Recently massive doses of MTX in the range of 3-30 gm/m^ 
in conjunction with leucovorin-rescue have been 
administered (Djerassi et al, 1972). These large doses 
were administered as an intravenous bolus or as an 
infusion from 4-42 hours in duration (Hande, Donehower 
and Chabner, 1978). In addition to variation in the dose 
infused, the dose of leucovorin was also varied from
3-40 m g / m ^  given by the IV, IM or oral routes every 6 
hours commencing at the end of infusion until the 
observed plasma level of MTX achieved was less than the 
toxic level (Sadee, 1980). The level associated with risk 
of MTX toxicity after 24, 48, and 72 hours is shown in 
Table 2.
Toxicity
During MTX therapy, there are a number of toxic 
side-effects, some of which are related to folate stress 
and may be life threatening (Vogler et al, 1979). The 
main manifestations include :-
1. Hepatotoxicity
Hepatic fibrosis was found in 11 of 43 patients 
treated with MTX for psoriasis (Robinson et al, 1980) and 
11 out of 44 patients by Dahl, Gregory and Scheuer
(1972), cirrhosis was found in another 6 patients 
(Robinson et al, 1980 ). The prevalence of cirrhosis and 
fibrosis was significantly greater in patients treated
TABLE 2
Shows the toxic level and the toxicity risk 
after 24, 48, 72 hours (Nirenberg.et a 1, 1977)
Time After Administration
24
Hours
48 72
MTX Plasma levels (molar) lO-5 10-6 10-7
Toxicity risk:
number patients/all patients 28/74 
with high MTX level
25/68 20/90
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using frequent small doses (2,5 mg orally daily for 
between 2-5 days) than in those treated with intermittent 
large doses (10-25 mg either orally or intramuscularly at 
intervals of 1-4 weeks). Hepatic fibrosis and cirrhosis 
have been attributed to treatment with MTX in patients 
with leukaemia (C o l s k y , Greenspan and Warren, 1955; 
Hutter et a l , 1960). Less severe abnormalities of liver 
histology were reported in patients treated for benign 
ocular disease (Hersh et a l , 1966). Liver cirrhosis or 
fibrosis can only be ascertained by liver biopsy since 
liver function tests are not diagnostic (Weinstein, 
1973).
2. Pulmonary complications
Pulmonary complications have been reported in 
patients treated with MTX for acute leukaemia (Clarysse 
et al, 1969 ; Robertson, 1 970 ; Rawbone et a l , 1971;
Everts, Westcott and Bragg, 1973) and skin diseases 
(Filip et al, 1971; Goldman and Moschella, 1971).
Although MTX pneumonitis has not been considered 
dose-related (Clarysse et a l , 1969; Goldman and
Moschella, 1971; Rosenow, 1972; Everts et a l , 1973) it 
has never been reported in patients receiving less than 
20 mg per week. The syndrome occurred in patients who had 
been treated with the drug for periods ranging from 
12 days-5 years (average 138 days). The total dose 
received was between 40 and 6500 mg. Some patients were
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also receiving corticosteroids at the time that the 
pulmonary disease developed (Goldman and Moschella, 
1971 ) .
3. Neurotoxicity
Severe neurotoxicity has been reported following MTX 
administered intrathecally (IT) (Wilson and Norrell, 
1 969 ; Norrell et a l , 1 974 ). Of 231 patients, 13 were
found to have leucoencephalopathy after IV and IT MTX 
administration (Price and Jamieson, 1975); 9 out of 20 
patients developed leucoencephalopathy after IV high-dose 
MTX (Aur et al, 1978 ) .
Recently Bowles et al (1981) reported that no 
abnormalities of the brain were found in 18 patients 
suffering from osteosarcoma treated with high-dose MTX 
and leucovorin-rescue. The level of MTX in cerebrospinal 
fluid after intrathecal administration averaged 13,8 
times that of the serum concentration (1,7 x 10“ ^M) 
(Bleyer, Drake and Chabner, 1973). These observations 
suggest that the neurotoxicity associated with 
intrathecal MTX is due to prolonged exposure to a high 
concentration of drug in the tissues of the central 
nervous system.
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4. Renal toxicity
Link et al ( 1 976 ) suggested that high-dose MTX 
therapy regularly produced a reversible decline in 
glomerular filtration rate (GFR); if sufficiently severe 
the local renal toxicity may contribute to development of 
systemic toxicity due to inadequate clearance of MTX.
The same authors reported a correlation between 
lowered creatinine and inulin clearance and MTX-induced 
renal toxicity. A case of fatal renal failure in a 
patient treated with MTX showed severe histological 
damage (Ahmed, Shen and Bleyer, 1978),
Changes in plasma urea correlated with clinical 
indices of renal function, the urea rising as the other 
symptoms progressed. In those patients who recovered, 
the urea returned to normal. In patients who developed 
severe toxicity or in some patients with only moderate 
toxicity, decrease in the renal clearance of both inulin 
and PAH occurred (Condit, Chanes and Joel, 1969).
The complication of acute renal failure with high 
doses of MTX is particularly serious because MTX is 
mainly eliminated {> 90%) by the kidneys (Jaffe and Paed, 
1972). For renal damage due to crystallisation of 
metabolites see Renal Excretion, page 22 «
5. Bone marrow toxicity
In sequential bone marrow biopsies of 3 patients 
receiving high-dose MTX with leucovorin-rescue, initial 
accumulation of cells in GI-S phase (Day 1) were followed
16
by a significant proliferative response (Days 4-7) and 
return to pretherapy values (Krishan et al , 1976) in one 
patient, in bone marrow samples of the third day, 90% of 
the cells were blasts. At Day 7, 10% of the cell in the 
bone marrow v/ere blasts.
Avoidance of Methotrexate Toxicity
The toxicity of MTX with and without leucovorin was 
studied in one patient, who, when given 2.5 mg MTX daily 
for 8 days, developed mouth ulceration and leukopenia, 
however doses of 45-60 mg daily for 21 days were 
tolerated when covered by simultaneous parenteral 
administration of 3 mg leucovorin (Burchenal and 
Kingsley-Pillers, 1951).
Toxicity of MTX to organs such as bone marrow is 
dependent on both the duration of exposure to the drug 
and its extracellular (plasma) concentration. Concen­
trations of leucovorin of 10"*7m , 10“ ^M and 10” 3m are
required to rescue normal cells exposed to a level of 
MTX of 10”7{^  ^ 10”^M and 10"^M respectively (Pinedo et al, 
1 976 ). The administration of MTX must be stopped 
immediately if toxicity occurs. The use of thymidine to 
restore bone marrow activity has been claimed to give 
better results than leucovorin (Howell, Krishan and Frei,
1979), MTX-induced pulmonary changes have been treated 
by administration of prednisone (Schwartz and Kajani, 
1969) and by daunorubicin (Pasquinucci, Ferrara and 
Castellari, 1971).
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Renal damage is avoided by prehydration of the 
patient and the administration of bicarbonate to produce 
an alkaline urine as MTX and its metabolites are acidic 
compounds and alkali increases their solubility in urine 
(Hande et al, 1978).
PHARMACOKINETICS
Absorption
1. Oral
Doses of MTX below 30 mg/m^ are well absorbed with 
peak serum levels appearing after 1-2 hours. Slow 
absorption of small doses (peak after 4 hours) was seen 
in 5 out of 18 patients studied ( Freeman-Narrod, 1962).
The levels were determined by a fluorimetric method. In 
half of the patients they also found a definite slowing 
in the rate of absorption over a 6 week course of 
therapy. With doses in excess of 80 m g / m ^ , the extent of 
absorption was reduced by 50-70% (Henderson, Adamson and 
Oliverio, 1965; Wan et al, 1974). The kinetics were 
studied following the administration of radiolabelled 
MTX.
McVie et al (1981 ) studied high-dose oral MTX. 
250 mg of MTX in divided oral doses (50 mg each dose) 
every 2 weeks was administered to 9 patients followed by 
15 mg leucovor in four times daily for 2 days. The 
biological specimens were analysed by enzyme immunoassay
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(EMIT). Although the area under curve was always less 
than the equivalent IV dose, there was no evidence of 
malabsorption of the drug,
2. Intramuscular administration (IM)
The gradual absorption of drug from the IM site 
offsets the rapid fall in serum levels during the 
initial distribution phase (Freeman-Narrod et al; 1975) a 
fluorimetric assay was used.
3. Intrathecally (IT)
After IT injection of MTX absorption from the 
central nervous system, equilibration into the plasma 
compartment proceeded slowly. IT administration of 
10-15 mg/m^ resulted in plasma levels above 1Q“^M for 2-3 
times longer than after the same doses administered 
intravenously (Jacobs et al, 1975). The authors used a 
DHFR inhibition method.
4. Intravenous and infusion administration
This is preferred as very high doses can be 
administered by this route.
Distribution
After IV administration the disappearance of MTX 
from plasma is triphasic (Bleyer, 1978), the first 
half-life (t a ) is due to distribution and the second 
half-life ( t 3 ) is associated to renal clearance. The 
third half-life ( t ^ y ) is thought to reflect the entero- 
hepatic circulation of MTX (Bleyer, 1 978 ). After an IV
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dose of 80 mg/m^ MTX is concentrated in liver with 
liver;plasma ratios of 4:1 at 3 hours and 8:1 at 24 
hours.
MTX is readily transported into human skin after 
parenteral administration (Comaish and Juhlin, 1969) but 
not after topical application (Fry and McMinn, 1967; 
McCullough and Weinstein, 1974).
Distribution of MTX into cerebrospinal fluid, plasma 
and peritoneal cavities occurs slowly and if these spaces 
are pathologically increased as in ascites or pleural 
effusion, they act as a reservoir prolonging the presence 
of MTX in the plasma compartment (Wan et al, 1974).
Intra-arterial injection of the MTX leads to higher
tissue levels in the region supplied by the artery than 
after intravenous injection (Anderson et al, 1970), 
These slightly higher levels are probably clinically 
insignificant in comparison to the substantial risks of 
intra-arterial infusion.
1. Plasma protein binding
In man, 45-51% of MTX in plasma was found to be
protein-bound (Henderson et al, 1965; Wan et al, 1974)
using ultrafiltration to separate bound and free drug, 
Leigler et al (1969) and Taylor and Halprine (1977) 
calculated that 70% of MTX was bound in plasma. Steele 
et al (1979) estimated the plasma protein binding for MTX 
in vitro by a radioimmunoassay measurement on ultra­
filtrate, in which continuous filtration overcame many of
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the membrane binding problems. The percentage of MTX 
bound to serum protein remained constant at 95.11%+2,26 
(SD) over the range 1 x 10“ ^M to 3 x lO'^M. No great 
change in the protein binding occurred until the serum 
concentration exceeded 5 x 10"^M. At a concentration 
greater than this the free drug proportion increased much 
more rapidly than the total serum concentration.
These differences reflect the non-comparability of 
different methods of studying protein binding. Highly 
bound acidic compounds such as aspirin and para-amino- 
hippurate can displace MTX from its plasma protein 
binding sites (Leigler et al, 1969).
Metabolism
The known routes of metabolism of MTX in man are 
shown in Figure 3. The major metabolite of MTX is 
7-hydroxymethotrexate (7-OHMTX). 7-OHMTX was isolated 
and identified in human urine after high-dose therapy 
(> 50 mg/kg) (Jacobs et al, 1976).
Jacobs et al ( 1 977 ) reported that 7-OHMTX was not 
observed in patients following low-dose therapy 
(< lOmg/kg) and suggested that the production of this 
metabolite was dose-dependent. However Chan et al (1980) 
reported that 7-OHMTX production was not dose-dependent 
and was found in human plasma in patients receiving such 
doses.
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FIGURE 3 The metabolic pathway of Methotrexate.
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7-OHMTX has itself been shown to be an inhibitor of 
mammalian dihydrofolic acid reductase in vitro (Jacobs et 
al, 1977); although it is 200-fold less potent than MTX. 
It is also 4 to 5-fold less water soluble than the 
parent compound, and may cause renal damage due to 
crystallisation in the tubules (Jacobs et al, 1976),
4-Amino-4-deoxy methylpteroic acid (DAMPA or
APA) is produced by the removal of the glutamate residue 
from MTX by cleavage of the pteroate-glutamate peptide 
bond; it has been suggested that it is produced by the 
carboxypeptidase of some intestinal bacteria (Donehower 
et al, 1979), during enterohepatic circulation of MTX. 
However it may also be present as a contaminant in some 
IV preparations (Chatterji, Frazier and Gallelli, 1978).
DAMPA is also much less soluble than MTX; the limit 
of solubility of this compound suggests the possibility 
that renal precipitation may occur (Donehower, 1980).
DAMPA is a potent inhibitor of dihydrofolic acid 
reductase although the concentrations present in plasma 
are likely to be low (Kessel, 1969).
Theoretically, DAMPA could be metabolised in 
a manner similar to the oxidation of MTX giving rise to 
7-hydroxy-4-amino-4-deoxy-M^ -methylpteroic acid (7-OH- 
DAMPA) (Valerino et al, 1972) as a further metabolite.
The major intracellular metabolites of MTX are the 
polyglutamates (Hendel, 1978). Following passage into 
cells, MTX is converted to a series of polyglutamates by
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the addition of glutamyl residues. These may be retained 
within the tissues for up to 3 months before being 
degraded by pteroyIglutamyl-y-glutamyl carboxypeptidase 
and excreted via both the intestinal and the renal routes 
as MTX (Baugh, Krumdieck and Nair, 1973), Nair and Baugh
(1973) synthesised a series of 6 MTX polyglutamates 
ranging from MTX diglutamate (MTXG1) to MTX hepata- 
glutamate (MTXG6), andelevated their biological activity.
MTXG1 and MTXG2 have been found in human red blood 
cells (Baugh et al, 1973) while MTXG1 has been found in 
human liver cells (Jacobs et al, 1977); MTX polglutamates 
are also strong inhibitors of dihydrofolic acid reductase 
activity (Hendel, 1978).
Excretion
1. Renal excretion
The major route of elimination of MTX at low-dose 
( < 30 mg/m2 ) is renal excretion ( >80%) (Huffman et al, 
1973 ). About 50% of infused high-dose MTX was recovered 
in a 6-12 hour collection of urine post infusion (Stoller 
et al, 1975). Renal clearance of MTX in 15 patients with 
steady-state plasma levels ranging from 2 x 10“ ^M to 
4 X 10“ ^M was between 144-217 ml/minute with a mean of 
179. This indicates that MTX is not only filtered but 
also actively secreted by the renal tubules and that MTX 
clearance is not directly related to the level of free 
MTX presented to the kidney (Liegler et al, 1969).
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It has been suggested that renal secretion might be 
reduced by co-administrât ion of salicylate or para- 
aminohippurate (Leigler et al, 1969) giving a higher 
plasma concentration achieved for the same dosage, 
however this is balanced increased free MTX in the GFR. 
Pretreatment of monkeys with probenecid blocks renal 
tubular secretion of MTX (Bourke et al, 1975) and this 
property of probenecid has been exploited in order to 
slow elimination of MTX, thereby allowing a reduction in 
dosage.
The low solubility of MTX in urine creates a risk of 
crystallisation in the intratubular lumen. Solubility of 
MTX falls from 20 mM to 2 mM when the pH of the medium is 
reduced from 6.9-5.7 (Stoller et al, 1975). As shown in 
Table 3 the solubility of 7-OHMTX and DAMPA are much 
lower than MTX so there is also a possibility of renal 
damage due to precipitation of these metabolites in the 
renal tubules (Donehower, 1980) despite their reported 
lower plasma concentrations,
2. Biliary excretion
In man 6.7-9% of the administered dose has been 
recovered by duodenal aspiration during the first 24 
hours. Only a trace amount of MTX (i.e. less than 2% of 
the dose) was recovered in the 24-48 hour period of bile 
collection (Shen and Azarnoff, 1978).
TABLE 3
Aqueous solubility of MTX and Metabolites
Compound mM
pH5 pH6 pH7
MTX 0.85 3.4 19.89
7-OHMTX 0.27 0.78 3.3
DAMPA 0.15 0.31 2.6
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3. Extra-renal excretion
The ratio of breast milk MTX to plasma MTX concen­
tration was 0.08:1 (Johns et al, 1 972 ). A Low level of 
MTX in saliva was found following 30 mg/m^ iv dose of MTX 
(Huffman et al, 1973).
METHOTREXATE ASSAYS
Due to the wide use of MTX and high risk of 
toxicity, it is essential to monitor the level of the 
drug in the plasma during and following therapy (Bertino 
and Isacoff, 1978). Several techniques have been used 
for measurement of MTX in biological fluids.
Biological Assay
Such techniques depend on inhibition of growth of 
streptococcus faecalis by incubation with MTX over 24 
hours. The concentrations of MTX are calculated from the 
relative diameter of the zone plotted against the 
logarithm of the concentration of drug (Burchenal et al, 
1951). Although this method has a sensitivity of 
2 x 10"^M, it has a poor specificity because other 
substances in biological fluids with growth inhibitory 
properties may give falsely elevated results. The 
precision is +12% and the assay is time consuming. 
Results are seldom available fast enough to influence the 
rescue procedure which is decided on clinical criteria.
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Fluorimetric Methods
A fluorimetric method for the determination of MTX 
in biological fluids was first reported by Freeman 
(1957). Following protein precipitation by trichloro­
acetic acid, potassium permanganate solution was used to 
oxidise MTX to 2,4-diamino pteridine 6-carboxylic acid 
(Figure 4). The sensitivity of the method was 1 x 10"^M 
but it had poor specificity as metabolites yielded an 
identical fluorescent product.
Chakrabarti and Bernstein (1969) modified the 
Freeman method. A protein precipitation step including 
heating significantly improved the recovery by releasing 
bound MTX from the precipitant. Despite the increased 
recovery the sensitivity of this method was the same as 
Freeman’s (1 x 10” ^M) and suffered from the same problem 
of low specificity.
Recently an improved spectrofluorimetric method was 
reported using sodium bisulphite instead of hydrogen 
peroxide and Tris buffer pH 8.5 instead of phosphate or 
acetate buffer pH5 in the oxidation procedure (Kinkade, 
V o g 1er and Dayton, 1974). In addition a long extraction 
procedure was employed. The method was linear over a 
wide range of plasma concentrations but had a sensitivity 
of only 2 x 10” *^ M of MTX in plasma despite a 10-fold 
improvement in fluorimetric intensity over the Freeman 
assay. The method had high recoveries (93%) and was 
highly reproducible.
CH H
fi-
COOH 
Ç H ^  
Ç H ^  
CH ■COOH
COOH
FIGURE 4 The oxidation of MTX to yield a fluorescent product,
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Generally the fluorimetric methods lack specificity 
due to measurement of MTX metabolites.
Dihydrofolic Acid Reductase Inhibition Methods
The decrease in enzyme activity following inhibition 
by MTX may be measured by following the decrease in 
absorbance at 340 nm as NADPH is oxidised to NADP during 
reduction of dihydrofolic acid to tetrahydrofolic acid 
(Bert ino and Fischer, 1 964 ). The sensitivity of this 
method is 2 x 10"^M but there is interference with MTX 
metabolites or reduced folates.
Rothenberg (1965) produced a radioenzymatic assay 
for MTX using folic acid reductase (obtained from chicken 
livers) to reduce the tritiated folic acid to 
tetrahydrofolic acid. Addition of MTX to the incubation 
mixture inhibited the reaction. From this MTX could be 
quantitated and standardised.
Falk et al (1976) produced an enzymatic assay for 
MTX in serum and cerebrospinal fluid based on inhibition 
by MTX of DHFR from bacteria. The quoted sensitivity was 
also 2 X 10”^M and again specificity was not reported. 
Radioimmunoassay
Radioimmunoassays have been developed for MTX 
(Levine and Powers, 1974) using either rabbit or goat 
antisera raised against MTX-hemocyanin conjugate. As 
would be expected these assays are highly sensitive, 
having a limit of detection of 2 x 10” ^M; the methods 
lack specificity and have not achieved widespread usage.
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Hendel, Sarek and Hvidberg (1976) used MTX
conjugated to methylated bovine serum albumin. The 
sensitivity of their optimised assay was 4 x 10”^M, there 
was little cross-reactivity with folic acid, leucovor in 
or tetrahydrofolic acid. The authors did not test for 
cross-reactivity with MTX metabolites.
Aherne, Piall and Marks (1977) developed a radio­
immunoassay method for MTX using an MTX-ovalburnin
conjugate as antigen. This method has been in use for 4 
years, during which time the label has been changed from 
tritium to (A h e r n e , Piall and Marks, 1978) and
finally to a (Kamel and Gardner, 1978).
The sensitivity of the method was 2 x 10“^M. The 
quoted specificity gave 31% cross-reactivity with DAMPA 
but less than 1% for 7-OHMTX.
Enzyme Immunoassay
A homogeneous enzyme immunoassay for MTX in plasma 
was developed by Gushaw and Miller (1978) and is now
marketed as an EMIT kit by the Syva Corporation. The
method is illustrated in Figure 5'. The diluted plasma 
sample is mixed with a reagent which contains antibodies 
to MTX together with substrate for the enzyme glucose
6-phosphate dehydrogenase (G6PDH). Binding occurs to any 
MTX or metabolite in the serum or plasma which is 
recognised by the antibody. A second reagent containing 
MTX labelled with the enzyme G6PDH is then added. The 
labelled drug combines with any remaining unfilled
Fig 5
free
NAD NADH
enzyme active 
substrate products
bound
enzyme inactive
FIGURE 5 The mode of action of a homogenous enzyme 
immunoassay for a drug.
E = Enzyme
A  t= Drug
*= Antiserum
28
antibody binding sites, and the enzyme activity is 
thereby proportionately reduced, as the antibody-bound 
enzyme drug conjugate is inaccessible to the substrate. 
The residual enzymatic activity is directly related to 
the concentration of MTX present in the serum or plasma. 
The active enzyme converts nicotinamide adenine NAD to 
NADH, resulting in an absorbance change that is measured 
spectrophotometrically at 340 nm. Interference from serum 
G6PDH activity is avoided by use of NAD which functions 
as a coenzyme only with the bacterial (Leuconostoe 
Mesenteroides) enzyme used in the assay and not with 
human G6PDH which requires NADPH.
The sensitivity of the method is 2 x10"^M, however 
specificity is not absolute due to cross-reactivity of 
the antiserum with some metabolites, especially DAMPA 
(Gushaw and Miller, 1978).
Double Antibody Enzyme Immunoassay for Methotrexate
Marks et al (1978) produced an enzyme - immunoassay 
for measuring MTX in plasma by conjugating beta-D- 
galactosidase to MTX by means of a mixed anhydride 
reaction and used a double-antibody immunoassay. The 
quoted sensitivity was 4 x 10“ ^M with a coefficient of 
variation of 4-15%. There was 40% cross-reactivity with 
DAMPA. The disadvantage of this assay was the need for 
overnight incubation. Al-Bassam et al (1979) improved 
this assay by using a precipitated complex of first and 
second antibodies which markedly increased the speed of
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the assay. The improved assay had a sensitivity of 
2 X 10” ^M but the cross-reactivity with DAMPA remained a 
problem.
High Performance Liquid Chromatography
High performance liquid chromatography (HPLC) has 
been used for the analysis of MTX and other 
anti-neoplastic drugs. Montgomery et al (1977 ) reported 
a reverse-phase HPLC procedure for MTX and related folate 
analogs, however MTX metabolites were not examined.
Nelson et al ( 1977 ) used HPLC with fluorescence 
detection to estimate MTX in biological fluids following 
oxidation of MTX by potassium permanganate solution (see 
Figure 4). 2-Hydroxy fol ic acid (fluorescent oxidation 
product 2,4-dihydroxypteridine 6-carboxylic acid) was 
used as internal standard. The sensitivity of this 
method was 2 x 10“ ^M. MTX in the trichloroacetic acid 
extract could be measured with a UV detector at 305 nm, 
but the sensitivity of UV detection was 8 x 10"^M. The 
calculated recovery was only 40%. The authors did not 
study interference by MTX metabolites but these would be 
expected to interfere as a non-selective oxidation 
procedure was used.
Lankelma, Kleijn and Termond (1978) reported an 
assay for MTX and 7-OHMTX by HPLC in which a short 
reverse-phase column was used to concentrate the sample, 
this was eluted with tap water on to an an ion-exchange 
column.
30
Cerebrospinal fluid (CSF) and plasma were deprotein- 
ised by adding a solution of trichloroacetic acid in 
0.1 M hydrochloric acid. The sensitivity was 2 x 10"^M 
but recovery was suboptimal (< 70%). The precision was 
5% at a concentration of 4 x lO^^M (n = 3).
The authors did not report on the interference by 
MTX metabolites and no internal standard was used.
Watson, Cohen and Chan (1978) separated and 
determined MTX and its metabolite 7-OHMTX in human plasma 
using anion exchange chromatography. Detection was at 
254 nm using N - [ 4 [ [ ( 2 , 4-diamino-6-quinazolinyl ) methyl- 
amino] benzoyl]] aspartic acid as an internal standard. 
Perchloric acid deproteinisation with ammonium sulphate, 
followed by extraction with an organic solvent was used 
for sample clean-up.
The quoted sensitivity was 2 x 10”^M or 1 x 10“^M 
using detection at 254 nm or 315 nm respectively. The 
precision at 1 x 10"^M was 3% (n - 8). Leucovorin and 
folic acid did not interfere with this assay. Twenty-six 
per cent recovery for 7-OHMTX was seen under these assay 
conditions. The authors did not discuss other 
interferences.
Donehower et al ( 1 979 ) reported an HPLC assay that 
allowed determination of DAMPA, as well as MTX and 
7-OHMTX following an anion-exchange extraction procedure.
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Two HPLC column systems were used, a preparative 
column (30 cm x 0.78 cm ID) and an analytical column 
(30 cm X 0.3 9 cm ID). Recoveries for MTX and DAMPA were 
determined using radiolabelled standards. The reported 
recoveries were 77%, 79% for MTX and DAMPA from urine and 
90% and 89% for MTX and DAMPA from plasma. They did not 
report a figure for the recovery of 7-OHMTX.
Howell et al (1980) have separated MTX, 7-OHMTX and 
DAMPA from human plasma. Polyglutamates were not studied 
since they were obscured by endogenous plasma components. 
The sensitivity of this method was 2 x 10” ’^M for MTX, 
7-OHMTX and DAMPA and the quoted precision was a 
coefficient of variation (CV) of 10-20%.
Few of these assays incorporated an internal
standard. The extraction procedures employed gave a
wide range of recovery figures particularly for the 
metabolites for which the assays were not optimised.
None of the authors mentioned above reported
the investigation of possible interference by other 
anti-neoplastic drugs. This is surprising in view of 
the common use of more than one drug in current
chemotherapeutic regimes.
AIMS
The aims of this study were:-
(1) To develop a sensitive, accurate, precise method for 
MTX and its metabolites in biological fluids.
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(2) To study the pharmacokinetics in patients treated 
with high and low doses of MTX and examine the 
clinical relevance of MTX assay and measurement of 
metabolites to the safe use of MTX in vivo.
CHAPTER 3
DEVELOPMENT OF A HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC 
METHOD FOR THE ESTIMATION OF METHOTREXATE AND ITS
METABOLITIES
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INTRODUCTION
The several high performance liquid chromatography 
(HPLC) methods used to achieve specificity for MTX by 
chromatographic separation of the drug from its 
metabolites, and published before the beginning of this 
study, are reviewed here (for more details see 
Chapter 2).
All extraction procedures involved precipitation of 
the proteins by trichloroacetic acid or perchloric acid. 
In some, the supernatant was injected directly onto the 
HPLC column (Nelson et al, 1977 ; Lankelma et al, 1 978 ). 
In others the protein-free plasma was extracted directly 
with organic solvent (Howell et al, 1980). Watson et al
(1978) used an organic solvent extraction following 
ammonium sulphate addition. Adsorption extractions were 
carried out using anion-exchange resin (Donehower et al, 
1979).
Only Nelson et al (1977) and Watson et al (1978) 
used an internal standard in order to improve precision.
Reverse-phase chromatography was used by some 
authors (Nelson et al, 1977 , Lankelma et al, 1978;
Donehower et al, 1979 and Howell et al, 1 980 ) and others 
used anion-exchange chromatography (Lankelma et al, 1978; 
Watson et al, 1978). Most authors used an ultraviolet 
(UV) detector while Nelson et al ( 1 977 ) found that the 
sensitivity for MTX could be increased about 40-fold 
(2 X 10“8m ) when a fluorescence detector was used.
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The major metabolite, 7-OHMTX was detected in plasma 
by Watson et al (1978) and Howell et al (1980) and in 
urine by Donehower et al (1979).
DAMPA was reported in urine by Donehower et al
(1979) and in serum by Howell et al(1980). Polyglutamates 
have been chromatographed from standard solutions (Howell 
et al, 1980) but not from plasma because of failure to 
separate these from endogenous components.
Not all authors have quoted figures for the 
recovery, precision, sensitivity, accuracy and linearity 
of their methods, hence the methods cannot be compared 
di r ectly. Surprisingly none of the authors quoted 
checked for possible interference by other drugs.
A resume of the performance characteristics of 
published HPLC methods is presented in Table 4. 
lon-Pair Chromatography
Many organic molecules contain highly polar groups 
which make them difficult to chromatograph satisfactorily 
using polarity separation. They may however be retained 
by using ionised surfactants, these lipophilic ions 
adsorb to reverse-phase packings, ions of opposite charge 
form ionic bonds with them, thereby causing retention. 
For example, the sulphonic acids are ionised throughout 
the pH range and are useful in the analysis of cationic 
compounds (Knox et al, 1 977 ). An ion-pair may be 
described as shown in the equation:
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S"aq + P+aq ^ ^^org
Where S" is solute ion, P"^  is pairing ion, and SP is 
solute ion-pair. The extraction coefficient (Egp) of the 
ion-pair is:
E g p  = [SPoirg]/[S'"aq] [P'^aq]
The distribution coefficient (Dg) of the solute is 
defined by:
D s  = [ S P o r g ] / l S " a q ]  = [ E g p ] [ P + a q ]
retention volume of analyte - to
Definition: k ' - ------------- ----
retention volume u n r e t a i n e d  peak (to)
Since k ' is proportional to Dg (distribution of the 
solute) in reversed-phase chromatography, k' will be 
proportional to the pairing ion concentration, i.e. k ' 
increases with increasing ion-pair concentration and also 
with increasing chain length of the ion-pairing agent. 
MATERIALS AND EQUIPMENT
Materials ' '-4\'
MTX, DAMPA and calcium leucovorin were donated by 
Lederle (Gosport, Hants, England). MTX diglutamate and 
MTX triglutamate were made available by Professor 
C M Baugh, University of South Alabama, USA. 7-OHMTX was 
a gift from Dr David G Johns (National Cancer Institute, 
Bethesda, Maryland, USA). 7-OHDAMPA was synthesised in
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vitro and the identity confirmed by electron impact mass 
spectrometry and nuclear magnetic resonance spectroscopy 
(Chapter 4). L-tryptophyl L-glutamic acid, used as 
internal standard, was obtained from the Sigma Chemical 
Company (Dorset, England). Hexanesulphonic acid was 
Fisons HPLC grade (Fisons Scientific Apparatus, 
Longborough, England). The anion-exchange resin Dowex 
1-x2 was obtained from Bio-Rad Laboratories (Watford, 
Hertfordshire, England), Acetonitrile, HPLC grade was 
obtained from Rathburn Chemicals (Walkerburn, 
Peebleshire, Scotland). Methanol was obtained from James 
Burroughs Limited (London, England) and all other 
reagents were from British Drug Houses (Pool, Dorset, 
England). Polypropylene Econo-columns (0,7 cm ID x 4 cm) 
with a 10 ml reservoir and porous 70 u polyethylene 
bed support were obtained from Bio-Rad (Watford, 
Hertfordshire, England),
Choice of L-Tryptophyl L-Glutamic Acid as Internal 
Standard (IS)
A variety of substances were investigated in order 
to find a suitable internal standard (IS). The only 
simple readily available compound which was both soluble 
and had an acceptable k ' was p-nitrophenol. However an 
internal standard should be structurally similar to the 
analyte and exhibit similar physiochemical properties; 
p-nitrophenol is unstable and was more readily extracted 
from aqueous solutions than MTX. L-tryptophyl L-glutamic 
acid was a more satisfactory alternative as it had a
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structure somewhat analogous to MTX, was available 
commercially, was found to have similar physiochemical 
properties to MTX in the analytical system and was 
resolved from MTX and its metabolites on the HPLC column. 
Apparatus
A Pye-Unicam HPLC system (Cambridge, England) 
consisting of an LC-XPS single piston reciprocating pump, 
a L C - u y  variable wavelength detector and a PM8521 single 
pen recorder were used.
The stainless steel column (10 cm x 5 mm ID) was 
obtained from Shandon Southern (Runcorn, England) slurry 
packed with 5 u CDS Hypersil (Shandon Southern) using a 
Shandon slurry packer and fitted with a valve adaptor 
(Shandon Southern). An 8050 Autosampler (Varian 
Associates, Walton-on-Thames, England), with a 20 ul loop 
was used for urine injection according to the 
manufacturers recommendation. Because of the limited 
amount of analyte available from serum extracts the 
operation of the autosampler was modified in order to 
reduce the dilution factor.
The autosampler used gas pressure to force the 
liquid through the sample line to the loop in the 
automatic valve injector. The volume of sample used is 
dependent on the dead volume of the sample line/injector 
and the gas pressure applied. By fitting a small gas 
pressure gauge and adjusting the outlet pressure to 
50 N/m2 it was possible to inject 20 ul of sample from a
38
100 ul aliquot using approximately 75 ul of the aliquot; 
manual injection when required was made via a Rheodyne 
7125 injection valye (Scotlab Instruments Sales Limited, 
Law, by Carluke, Scotland).
The data generated was handled by an Infotronic CRS 
304-40 integrator (Belmont Instruments Limited, Glasgow, 
Scotland).
METHODS,
Initial Chromatography
A reverse-phase material (CDS Hypersil) was used to 
separate MTX and its metabolites. The metabolites 
consisted of MTX diglutamate(MTXG,j ) MTX triglutamate (MTXG^)
7-OHMTX, and DAMPA with leucovor in and L-tryptophyl 
L-glutamic acid (IS). The liquid chromatographic method 
was developed as follows;
1 . Polarity investigation
Methanol was first used alone as a mobile-phase, to 
elute the MTX and its metabolites. Increases in polarity 
were effected by adding water to the methanol. The 
changes in k ' of MTX and its metabolites were studied.
2. pH control
The pH of the mobile-phase was controlled by using
0.05 M phosphoric acid (pH 2.2). Methanol : 0.0 5 M 
phosphoric acid (50:50, v:v.) was used initially. The 
effect of changes in polarity at this pH was examined.
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3. Ion-Pairs
Hexanesulphonic acid was used as ion-pair at a 
concentration of 5.3 mM in 0,05 M phosphoric acid.
Sample Preparation
1. Solvent selection
Two ml of an aqueous solution containing 8.8 uM MTX 
and 12 uM DAMPA standard was shaken in a Cl 4/Cl 5 Q + Q 
tube with 5 ml of one of the following solvents; ethyl 
acetate : isopropanol (10:1), dichloromethane, hexane, 
diethyl ether, cyclohexane and hexane containing 0.5-5% 
v/v amyl alcohol.
The contents of the tubes were shaken for 10 
minutes, and centrifuged for 10 minutes at 2000 g, 4 ml 
of the organic layer was transferred to a Cl 4/Cl 5 conical 
quick fit tube and the organic solvent evaporated to 
dryness at 50 “C under a stream of nitrogen The residue 
was dissolved in 100 ul of mobile-phase and 20 ul was 
injected onto the HPLC column. The recovery was 
calculated by external standarisation.
2. Solvent volume selection
Selection of the appropriate volume of ethyl 
acetate:2-propanol (10:1) was performed as in the 
experiments for solvent selection but with different 
volumes of ethyl acetate : 2-propanol ranging from 
1— 10 ml•
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3. Protein precipitation
Different volumes of precipitant (the volumes 
depending on the type) were added to 1 ml human serum 
containing 10 ug MTX standard (10 ug MTX/ml is equivalent 
to 2 X 10“ ^M), mixed and centrifuged for 10 minutes at 
2000 g . The supernatant was removed and extracted with 
the appropriate volume of ethyl acetate :2”propanol. The 
organic layer was evaporated to dryness under a stream of 
nitrogen in a water bath at 50"C. The residue was 
dissolved in 100 ul mobile-phase and 20 ul was injected 
onto the HPLC column. The methods of protein precip­
itation used were as follows;
(a) Perchloric acid
One ml of 0.69 ■ .M perchloric acid was added to 1 ml 
of serum, the sample spun and the supernatant removed. 
The pH of the supernatant was neutralised using 1M 
potassium hydroxide solution, and extracted with 5 ml of 
ethyl acetate : 2-propanol (10:1). The use of Molar 
potassium carbonate instead of potassium hydroxide was 
also studied. A further sample was extracted without 
neutralisation of the perchloric acid.
(b) Trichloroacetic acid (TCA)
0.3 ml of 0.53M TCA was added to 1 ml of serum. 
Following centrifugation, the supernatant solution was 
extracted directly with 5 ml of ethyl acetate;2 propanol 
(1 0:1 ).
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(c)
One ml of 0.4M sodium tungstate and 1 ml of 0.6M 
copper sulphate solution was added to 2 ml serum. This 
method yielded a heavy precipitate, the analysis was 
completed as in (b).
(d) Tungstic acid
0.3 ml 0.4M sodium tung state and 0.3 ml 0.3M 
sulphuric acid was added to 1 ml of serum. The 
supernatant was extracted as in (b).
• (e) Sulphosalicylic acid
One ml of 0.4M sulphosalicylic acid was used to 
precipitate the protein in 1 ml of serum. The analysis 
was completed as in (b).
(f) Heat precipitation
0.8 ml of 1M phosphate buffer pH 6.2 was mixed with 
2 ml serum, and a volume of water ranging from 0.5-4 ml 
was added to ascertain the volume of water which gave the 
highest recovery. The tubes were covered and heated in a 
boiling water bath for 3 minutes. After cooling, they 
were centrifuged at 2000 g and 20 ul of the supernatant 
solutions were injected on to the HPLC column.
4. Extraction from protein free supernatant solution
The efficiency of solvent extraction from this 
protein-free supernatant solution was investigated. The 
following modifications to the heat precipitation method 
were performed:-
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(a) Hexanesulphonic acid
Addition of hexanesulphonic acid to the supernatant 
in the range of 2.6-53 mM was tried.
(b) pH of the supernatant
The effect of altering pH of the supernatant was 
tested over the range from 2-8, by addition of either
O.IM phosphoric acid or 0.1M sodium hydroxide.
(c) Addition of solid ammonium sulphate (Watson et
al, 1978)
Following adjustment to pH4 with O.IM phosphoric 
acid, 5 gm solid ammonium sulphate was mixed with 2 ml of 
the protein-free solution, the mixture was extracted with 
ethyl acetate ; isopropanol (10:1 v:v).
(d) Activated charcoal
The supernatant was shaken with activated charcoal 
which was removed by filtering through micropore filters 
(0.22 u) (Millipore Corporation, Bedford).
The charcoal was washed with water, and the drug 
was eluted using a mixture of ethanol containing 0.28M 
ammonium hydroxide and was evaporated to dryness. The 
residue was washed in 100 ul mobile-phase and 20 ul was 
injected on to the HPLC column.
(e) Acetonitrile
Acetonitrile was used instead of ethyl acetate: 
isopropanol as extraction solvent in order to reduce 
contamination.
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(f) Liquid solid extraction (Donehower et al,1979) 
The supernatant was applied to a column of Dowex 
1-X2 anion-exchange resin, and 10 ml of distilled water 
was used to wash the column. MTX was then eluted using 
4 ml 2M acetic acid. The acetic acid was evaporated to 
dryness, the residue was dissolved in mobile-phase and 
20 ul was injected onto the HPLC.
The above method was modified as follows
(i) Supernatant and serum comparison
A comparison v/as carried out between applying 
the supernatant following protein precip­
itation to a Dowex 1-X2 column and applying 
the serum directly.
(ii) pH of the sample
The ionisation of MTX in plasma was increased 
by raising the initial pH to 8.0 and the 
effect on recovery from the column was 
determined.
(iii) Optimisation of column size
Columns ranging in height from 0.5 cm to 4 cm 
were studied in order to select the most 
appropriate column bed dimension.
(iv) Comparison of deionised and distilled water 
Columns were washed either with 10 ml 
deionised or distilled water after loading 
with serum containing MTX and DAMPA. The water
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portions were evaporated to dryness, the 
residue was dissolved in 100 ul mobile-phase 
and 20 ul was injected on to the column.
(v) Methanol
Following washing with water a further wash 
with 4 ml methanol was added and the methanol 
analysed by HPLC after evaporation to a 100 ul 
volume.
{vi) Elution with acetic acid/methanol
In order to determine the optimum concen­
tration for elution of MTX and its metabolites 
an experiment was carried out using different 
concentrations of acetic acid in methanol over 
the range of 5-40%.
(vii) Step-wise elution using two sequential elution 
steps
An experiment was carried out using 2 ml of 5% 
acetic acid in methanol followed by 4 ml of 
25% acetic acid in methanol as eluant. This 
procedure was compared with a single elution 
with 4 ml of 25% acetic acid.
Quantitation
The concentrations of MTX and metabolites in 
patients sera were calculated by ratio of the peak area 
of MTX (or one of its metabolites) to the peak area of 
the internal standard and comparison with the standard 
curve. The urine concentrations were determined by using 
an external standardisation procedure as previously
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described (Watson et al, 1980). The target standard was 
1.1 X 10“ ^M (50 mg/1), which was injected after every 
fourth sample. The values obtained from this "correction" 
standard were referred to the value for the 1.1 x 10“^M 
standard used in the calibration line. Any variation in 
drift standard was corrected and the correction was 
applied to the two unknown samples on either side of that 
standard.
Linearity and Sensitivity
The linearity was determined as a function of 
on-column sample weight by chromatographing 20 ul 
aliquots of aqueous solutions of MTX, 7-OHMTX and DAMPA 
over a concentration range of 0-500 mg/1 (1.1 x 10“^M) 
(equivalent to 0-10 ug on column weight).
Recovery
Solutions of MTX, 7-OHMTX and DAMPA in serum 
covering the range 0-50 mg/1 (1.1 x 10“^M) were analysed, 
the difference in detector response between the extracted 
and directly injected aqueous standard represented the 
absolute percentage recovery. Sera of known MTX 
concentrations to which internal standard had been added 
were assayed and the results compared with calibrators to 
represent relative recovery.
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Precision
1. Serum
The precision was assessed by determining MTX in 16 
serum extracts at each of 3 different concentrations, 
4.4 X 10"7m , 2.2 x 10-5% and 1.16 x 10-4% (q .2 mg/1, 
10 mg/1 and 53 mg/1).
2. Urine
Thirty-four direct injections from one patient's 
urine sample containing MTX, 7-OHMTX, DAMPA and 7-OHDAMPA 
were made using the autosampler and the results compared. 
No internal standard was used.
Accuracy and Specificity
1. Serum and urine
The accuracy was determined from recovery studies. 
The possibility of interference by a number of drugs, 
especially anti-cancer drugs, was checked by the addition 
of aqueous solutions of these to the same pooled serum as 
was used for the preparation of MTX solutions. The drugs 
studied were; cyclophosphamide, dacarbazine, fluorouracil 
vincristine, daunorubicin, doxorubicin, cis-platinum, 
cytarabine, trimethoprim, paracetamol and diazepam. The 
last two were added because of the frequency with which 
they were co-prescribed with MTX in patients under 
investigation in this hospital, and trimethoprim in view 
of the reported interference caused by this drug with 
other methods for determining MTX (Hande , Gober and 
Fletcher, 1980).
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2. Correlation with homogenous immunoassay 
Sera from 50 patients were analysed by immunoassay 
(EMIT) as well as by the HPLC method. The correlation 
was plotted.
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RESULTS
Initial Chromatography Method
1. Polarity investigation
The capacity ratio (k*) for MTX and its metabolites 
when methanol was used alone as mobile-phase was found to 
be zero. Increasing the polarity by adding water to 80% 
v/v failed to increase the retention of MTX or any of its 
metabolites except DAMPA which had k'of 1.
2. pH control
Using an aqueous component at pH 2.2 the k ' for 
leucovorin (L), L-tryptophyl L-glutamic acid (IS), 
MTX triglutamate (G2 ), MTX diglutamate (G-|), methotrexate 
(MTX), 7-hydroxymethotrexate (7-OHMTX) and 4-amino 
0_jfiethylpteroic acid (DAMPA) were 0.16, 0.41, 0.58,
0.58, 0.75, 0.75 and 2.25 respectively.
Table 5 shows the effect of increasing polarity at 
pH 2.2 on the reduced plate height (h value), capacity 
ratios (k*) and resolution factor (Rs) for MTX and its 
metabolites.
3. lon-pair
The elution pattern obtained using the mobile-phase 
with and without hexanesulphonic acid as ion-pair is 
shown in Table 6 , from which it can be seen that the 
resolution and efficiency were improved.
An acceptable mobile-phase composition for 
separation of MTX and its metabolites with internal 
standard was found to be methanol : 0.05M phosphoric acid
I s
I I,
TABLE 6
Comparison between solvent^ with and without Ion-Pair Agents
Solvent A 
k* Rs h
Solvent B 
k* Rs h
Leucovorin
MTX
7-OHMTX
DAMPA
0.66
Internal STD 1.8
3.3
3.5
4.58
5.5
11.1
2.3
1.8
0.16
3.16
50 1.23
69 4.46
66 5.15
96 5.6
33 6.6
24 8.3
60 18.1
7.6
1.38
1.01
1.5
2. 58
8.8
25
8,9
9.5
10.0
8.16
6.9
Solvent A: Methanol:0.05M phosphoric acid (pH 2.2) 30; 70
Solvent B: Methanol;0.05M phosphoric acid (containing 
5.3 mM hexanesulphonic acid) 30:70
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pH 2,2 containing 5.3 mM hexanesulphonic acid in 
proportions of 30:70 v:v. Subsequent experience indicated 
that minor adjustment to this eluent were needed to 
maintain an optimum separation.
The chromatogram of a standard injection of MTX and 
its metabolites with L-tryptophyl L-glutamic acid as 
internal standard using as mobile-phase methanol : 0 .05M 
H 3 P O 4 containing 5.3 mM hexane sulphonic acid (28:72) is 
shown in Figure 6 .
Optimised Liquid Chromatography Method
The mobile-phase consisted of 5,3 mM hexanesulphonic 
acid in 50 mmol/1 phosphoric ac id ; me thanol (72 : 28 ), the 
operating conditions were : temperature ambient; flow rate
1 ml/minute; wavelength 307 nm; chart speed 0.5 cm/ 
minute. Absorbance settings varied depending upon the 
samples injected.
Sample Preparation
1. Solvent selection
Ethyl acetate : isopropanol in proportions of 10:1 
were found to produce the highest recovery for MTX and 
DAMPA (Table 7).
2. Solvent volume selection
The best volume was found to be 5 ml of ethyl 
acetate : isopropanol in proportions of 1 0 : 1  to extract
2 ml of aqueous standard (Table 8 ).
0 015
Abs
307nnr
0 01
0 005
FIGURE 6 Chromatogram of MTX and metabolite standards with
L-tryptophyl L-glutamic acid as internal standard, 
peak identities are:
1. Leucovorine (L)
2. L-tryptophyl L-glutamic acid (IS)
3. MTX triglutamate
4. MTX diglutamate ( V
5, MTX (M)
6. 7-OHMTX (70)
7. DAMPA (D)
8. .7-OIIDAMPA (70D)
TABLE 7
Absolute Recoveries of MTX and DAMPA following Extraction from 
Aqueous Solution by Different Organic Solvents (n = 4) _______
Recovery Recovery
Organic Solvent of MTX of DAMPA
Hexa ne O 3.9%
Hexane + amyl alcohol 0 O
(the alcohol in concentration 
ranging from 0.5-5% v/V)
Cyclohexane O 6.3%
Diethyl ether O 38.8%
Dichloromethane 10% 13%
Ethyl acetate : 2-propanol (10:1) 78.6% 92%
TABLE 8
Absolute Recoveries of MTX and DAMPA following 
Extraction by Different Volumes of Ethyl Acetate: 
2-Propanol (10:1) (n - 4)________________________
ml of Ethyl Acetate: Recovery Recovery
2-Propanol (10:1) of MTX of DAMPA
1 30% 20%
2 30% 22%
3 53% 42%
4 63% 65%
5 80% 90%
6 76% 85%
7 77% 86%
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3. Protein precipitation
(a) Perchloric acid
The absolute recovery was low (< 30%) using either 
1M potassium hydroxide , 1M potassium carbonate or no 
neutralisation.
(b) Trichloroacetic acid
The absolute recovery was low (< 30%).
(c) Copper tungstate
No MTX was recovered,
(d) Tungstic acid
Recovery of MTX was zero.
(e) Sulphosalicylic acid
Low absolute recovery (< 35%) was obtained.
(f) Heat Precipitation
The effect of the volume of water on the absolute 
recovery after heat precipitation is shown in Table 9,
4. Extraction from protein-free supernatant solution
Direct extraction of the supernatant gave 14%
recovery. The following were modifications to the heat 
precipitation method.
(a) Hexanesulphonic acid
Addition of hexanesulphonic acid to the supernatant 
and extraction with ethyl acetate : isopropanol in ratio of 
1 0 : 1  gave no increase in absolute recovery (14%).
(b) pH of the supernatant
It was found that pH 4 yielded the highest absolute 
recovery but this was still less than 40% (Table 10).
TABLE 9
The Effect on the Recovery of MTX of Dilution of Serum before 
Heat P r e c i p i t a t i o n _____________________________________
Serum
Phosphate 
Buffer pH 6.2 Water Recovery
2 ml 
2 ml 
2 ml 
2 ml 
2 ml 
2 ml 
2 ml
Nil 
O. 8 ml 
O. 8 ml 
O. 8 ml 
O. 8 ml 
O. 8 ml 
O. 8 ml
Nil
0.5
1.0
1.5 
2
2.5 
3
Incomplete precipitation 
Incomplete precipitation 
75%
85%
95%
90%
93%
TABLE lO
The Effect of pH on the Extraction of MTX from a Protein 
Free Supernatant by Ethyl Acetate :Isopropanol____________
Recovery
2 10%
2.5 12%
3 14%
4 39%
5 30%
5. 5 21%
6 14%
7 14%
8 10%
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(c) Addition of solid ammonium sulphate
This procedure gave an absolute recovery of 74%. 
However the procedure gave rise to many peaks from blank 
sera which would interfere with the peaks obtained for 
MTX and its metabolites.
(d) Activated charcoal
The absolute recovery was 3.6%.
(e) Acetonitrile
The absolute recovery was 75% but interfering peaks 
were not found in extracts from drug-free serum
(f) Liquid solid extraction
This procedure showed a good absolute recovery (77%) 
and clean chromatograms for drug-free sera were obtained,
but the use of water as eluant resulted in lengthy
evaporation times,
(i) Supernatant and serum comparison
Better recovery was obtained when serum was 
applied directly (Table 11). This method was 
preferred since it showed the highest recovery 
as well as being the least time consuming,
(ii) pH of the sample
Raising the pH to 8,0 gave an increase in
recovery of 7-OHMTX from 6 6 % to 74%, MTX
remained at 90%.
TABLE 11
Recovery of MTX and Metabolites from Dowex 1-X2 Column before and 
after heat precipitation_____________________________________________
Recovery of Recovery of Recovery of
MTX 7-OHMTX DAMPA
Application of 67% 49% 73%
supernatant after 
heat precipitation
Direct application 90% 66% 85%
of serum
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(iii) Optimisation of column size
It was found that a 2 cm column was optimal 
for 1 ml of serum. Below 1 cm column capac­
ity was insufficient. Above 2 cm k ' was 
increased.
(iv) Comparison of deionised and distilled water
A proportion of the MTX was eluted by
distilled water, presumably due to its acidity 
(pH 5), Deionised water at neutral pH caused 
no elution,
(v) Methanol
Following washing by methanol very clean 
blanks were obtained.
(v i ) Elution with acetic acid ; methanol
It was found that a solution of 25% acetic
acid in methanol was the lowest concentration 
which yielded an acceptable recovery of MTX 
(Table 12). This eluant is an azeotropic
mixture and consequently improves the rapidity 
of the evaporation.
(vii) Stepwise elution
It was found that the two-step procedure gave 
a further increase in recovery resulting in 
95% retrieval of added MTX from serum.
TABLE 12
Effect of Acetic Acid on the elution by Methanol of MTX and 
DAMPA from Dowex 1-X2
Percentage of acetic acid Recovery Recovery
in methanol composition of MTX of DAMPA
0% 0% 0%
5% 65% 60%
10% 81% 87%
15% 84% 87%
20% 90% 89%
25% 96% 94%
30% 94% 94%
35% 95% 90%
40% 96% 94%
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Optimised Extraction Procedure
1. Serum
One hundred ul internal standard {as per Table 13) 
was added to 1 ml serum, the pH was adjusted to 8 with 
50 ul 0 . 2 M potassium carbonate solution and the sample 
applied to an ion-exchange column prepared by packing a 
Pasteur pipette with a 2 cm column of Dowex 1-X2. The 
column was first washed with 1 0 ml deionised water 
followed by 4 ml methanol. MTX and its metabolites were 
eluted using 2 ml of 5% acetic acid in methanol, followed 
by 4 ml of 25% acetic acid in methanol. The acid 
fractions were combined and evaporated to dryness under 
vacuum at 35 °C. The residue was dissolved in 100 ul of 
HPLC mobile-phase, vortexed for 15 seconds, centrifuged 
for 1 minute and 2 0  ul injected on the column via the 
autosampler.
For low concentrations of MTX the residue was 
dissolved in 25 ul HPLC mobile-phase and 20 ul of this 
injected manually on the column.
2. Urine
Direct injection of urine (20 ul) yielded satis­
factory chromatography of MTX and its metabolites.
TABLE 13
Internal Standard Concentration and Detector Attenuation 
used at different MTX Concentrations
MTX Concentration Range Stock IS Detector
mg/1________________M__________  g/1 AUFS
— 7
0-0.09 O - 2 X 10 0.25 0.04
-7 “6
0.09-0.9 2 X lO - 2 X 10 1 0.04
0.9 up 2 X 10 - up 5 O-16
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Linearity and Sensitivity
1. Serum and Urine
The assay for MTX was linear over the range 0-10 ng 
on column sample weight for extraction from serum with 
internal standard or for directly injected aqueous 
standard, equivalent to 0-50 mg/1 (0-1.1 x 10“ ^M) and 
0-500 mg/1 (0-1.1 x lO^^M) respectively.
The lowest detectable serum concentration (defined 
as a signal to noise ratio of 2) was 12.5 ug/1 
(2.75 X 10” 8m ) and for urine MTX 500 ug/1 (1.1 x 10"^M), 
equivalent to 10 ng on column.
Recovery
Absolute recoveries of MTX, 7-OHMTX and DAMPA from 
serum are detailed in Table 14. Recoveries relative to 
the L-tryptophy1 L-glutamic acid internal standard, as 
calculated by the ratio of peak areas, was found to be 
96.1+3.8 (n = 16) for MTX. As urine is injected directly 
on column, there was no need to determine recovery. 
Precision
The precision studies are summarised in Table 15. 
All except 7-0HÛAMPA fell below 6% CV.
Accuracy and Specificity
1. Serum and urine
None of the drugs examined interfered with the 
assay of MTX and its metabolites. Over 200 MTX-free sera 
have been assayed with no interference. Although no
TABLE 14
Absolute Recovery of MTX, 7-OHMTX and DAMPA 
from Serum (n = 16)
Compound Absolute Recovery (%)
X  +SD CV%
MTX 94.5 4.8 5
7-OHMTX 72.4 5.8 8.1
DAMPA 89.5 5.8 6.4
TABLE 15
Precision Studies on MTX in Serum (n = 16) and MTX and Metabolites 
in urine (n = 36)
Compound Matrix Concentration
Mass Units Molar Units
CV%
MTX
MTX
MTX
MTX
7-OHMTX
DAMPA
7-OHDAMPA
Serum
Serum
Serum
Urine
Urine
Urine
Urine
162 ug/1 
9.6 mg/1 
50 mg/1 
42.4 mg/1 
15.8 mg/1
71.1 mg/1 
6.68 mg/1
-7
3.56 X 10 M
2.1 X 10“\
-4
1.1 X 10 M
9.3 X 10"^M
3.35 X 10”^M
21.0 X 10"^M
1.98 X 10"^M
4.2
4.1
5.1 
2.6
5.6
2.7 
6.4
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extraction was used for urine samples, no interference 
was found here either. Over 200 MTX-free urines have 
been analysed and no interference noted.
2. Correlation with homogenous immunoassay
The correlation between the HPLC method and the 
homogenous immunoassay was found to be adequate for 
samples during the first 48 hours (Figure 7) but it might 
be effected by the presence of 7-OHMTX in the later 
stages or following low-dose therapy.
(moA) 
120
100
GO
60
40
20
• • 
• • n-60 
f-0.982 
gracient-1.16 
imercepl-1.37
20 40 60 80 100 120 (mg^
MTX(hPLC)
(mg/0
120
100
80
60
40
20
n-50 
r-O.973 
gracient-1.02 
Nercept- -1.37
20 40 60 80 too 120 (mg/O
KTTX+7-OMTX(HPLC)
FIGURE 7 Association between serum MTX concentrations 
measured by EMIT and;
a) Serum MTX measured by HPLC.
b) Tlie sum of serum MTX and 7-OHMTX 
measured by HPLC.
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DISCUSSION
In the initial studies, it was found that changing 
the polarity did- not improve the chromatography of MTX 
and its metabolites. Adjustment of pH to 2.2 gave 
increased retention (Table 5). The values which it was 
aimed to achieve were: reduced plate height < 10, k '
between 1 and 11 and resolution > 1.25,
Efficiency did not correlate with polarity, but with 
increasing polarity, leucovorin and DAMPA approached an 
acceptable k ' value. Resolution improved as retention 
volume increased, however the resolution between MTX and 
7-OHMTX and between MTXG 2 and MTXG-| were insufficient 
even at high k' . The addition of an ion-pairing agent 
gave further improvements in efficiency in that every 
component, except for leucovorin, had h = < 10 and k ' 
increased (leucovorin from 0.66 to 1.23 and DAMPA from
11,1 to 18.1) which were acceptable because baseline 
resolution was achieved between all components except G 2 
and G-) . Since these are expected to be present at 
approximately equal concentrations a resolution of 1 was 
accepted. Minor adjustments in the methanol content of 
the mobile-phase were subsequently required to maintain 
optimal resolution.
The wavelength used for detection of MTX and its 
metabolites was 307 nm since this was both optimal for 
the majority of analytes and clear of much potential 
endogenous interference. In the initial studies.
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ethyl acet a t e : isopropanol (10:1) was selected as the 
appropriate extracting solvent for plasma due to the high 
recoveries obtained from aqueous standards. It is highly 
polar, with a Hildebrand solubility parameter of 0.66. A 
minimum volume ratio of 2.5:1 of solvent to 
aqueous-phase provided maximum extraction which was 
still, however, only 80% for MTX. At this stage no pH 
adjustment was considered.
All of the protein précipitants gave rise to lower 
recoveries due to adsorption of MTX on precipitated 
plasma proteins (Chakrabarti and Bernstein, 1969), Copper 
tungstate and tungstic acid in particular produced a 
heavy precipitate in which MTX was presumably trapped, 
since no MTX was found in the supernatant when these 
compounds were used. It is of interest that other 
authors claim relatively high recoveries after protein 
precipitation (Watson et al, 1978; Howell et al, 1980). 
Their studies did not employ internal standards to 
control the extraction stage.
Heat precipitation with direct injection of the 
supernatant onto HPLC column yielded a relatively good 
recovery which could be further improved by dilution of 
serum with water. Although recoveries were of the order 
of 85%, sensitivity was low due to the dilution of the 
original plasma volume. It was therefore decided to 
extract this protein-free supernatant with the solvent
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system optimised as above. However the maximum absolute 
recovery using the extraction of protein-free supernatant 
was only 40%,
Direct application of serum to a Dowex 1-X2 column 
gave both higher recovery and higher sensitivity than 
application of protein-free supernatant to such a column 
due to the absence of dilution.
This liquid solid extraction had been used 
successfully by Donehower et al (1979) who did not record 
the absolute recovery of 7-OHMTX. In the current study, 
adjustment of the serum to pH 8 was found to be necessary 
to ensure that MTX and its metabolites would effectively 
interact with the ion-exchange resin; failure to perform 
this step led to reduced recoveries of 7-OHMTX. The 
methanol wash yielded cleaner blanks than the water wash 
employed by Donehower et al. Acidity is required to 
elute MTX and its metabolites, methanol/acetic acid was 
used since they form an azeotropic mixture with a 
consequent improvement in the rapidity of the evaporation 
step.
Any HPLC method which requires an extraction step is 
slower than a one- step assay such as an optical 
immunoassay. However, for pharmacokinetic studies it is 
necessary to measure the unchanged drug and also its 
major metabolites in plasma and urine. It has been
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reported that 7-OHMTX cross-reacts with the immunoassays 
by about 10% and this was borne out with the associations 
reported here.
Since the 7-OHMTX concentration may be higher than 
MTX concentration at the time at which toxicity is 
assessed i.e. 24 or 48 hours, this is a potential source 
of error.
The accuracy and sensitivity of the HPLC assay make 
the use of this technique preferable to the immunoassay 
procedure at low concentrations. The immunoassay 
procedure may be preferred where rapid result turnround 
is required during high-dose MTX therapy.
The HPLC procedure described here is highly 
sensitive and linear over a wide range and compares well 
with optical immunoassay which is an order of magnitude 
less sensitive and linear over only 5% of the range 
covered by the HPLC procedure (Farid, Watson and Stewart, 
1983). Recently HPLC methods were developed by Lawson, 
Dixon and Aherne (1981); Breithaupt, Kuenzlen and Goebel 
(1982) and Collier, MacLeod and Soldin (1982) which are 
less sensitive than the procedure described here. Chen 
and Chiou (1981) have since produced a cationic-exchange 
chromatography method which has the same sensitivity for 
MTX as this method.
Experience in this laboratory indicates that in 
order to produce acceptable between-batch precision, all 
extraction procedures should employ an internal standard.
60
Many workers quoted above did not use an internal 
standard. The internal standard L-tryptophyl L-glutamic 
acid, exhibited similar physiochemical behaviour to MTX 
in the analytical system and was ideally resolved from 
MTX and its metabolites on the HPLC column.
Other workers (Nelson et al, 1977; Watson et al,
1978 and Lawson et al, 1981) used an internal standard
which was not commercially available. The L-tryptophyl 
L-glutamic acid, used in these experiments is 
commercially available. The method presented here gives 
a simple reliable extraction procedure for the rapid 
determination of MTX, 7-OHMTX, DAMPA and 7-OHDAMPA in 
serum and urine by HPLC. This method could also detect 
the MTX diglutamate and MTX triglutamate.
So far as is known, this method is the only one 
which can be used to separate MTX and all metabolites 
(7-OHMTX, DAMPA, 7-OHDAMPA, MTX diglutamate and MTX
triglutamate) with an internal standard in one 
chromatogram. It is therefore suitable for studying the 
intracellular metabolites of MTX e.g. in erythrocytes. 
The procedure is sufficiently sensitive to detect MTX 
following administration of low doses used in e.g.
psoriasis and is to be preferred if low MTX concen­
trations are to be determined.
CHAPTER 4
IN VITRO SYNTHESIS OF METHOTREXATE METABOLITES
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INTRODUCTION
7-OHMTX, present in plasma is thought to be the 
product, not o f ■the cytochrome P450 system but of hepatic 
aldehyde oxidase. Aldehyde oxidase was first isolated 
from pig liver (Gordon, Green and Subrahmanyan, 1940) and 
identified as a flavoprotein which could catalyse the 
oxidation of a variety of aliphatic and aromatic 
aldehydes. In 1946, Knox demonstrated that aldehyde 
oxidase from rabbit liver could also catalyse the 
hydroxylation of a number of non-aldehydic heterocyclic 
compounds e.g. N-methylnicotinamide and quinine. The 
rabbit liver enzyme showed much greater activity than the 
enzyme from other mammalian species (Knox, 1946). Mahlar 
et al (1954) further purified the porcine enzyme and 
demonstrated the presence of molybdenum and iron.
Hurwitz (1955) achieved partial purification of the 
rabbit liver enzyme. Highly purified enzyme has been 
prepared from pig liver (Palmer, 1962), and rabbit liver 
(Rajagopalan, Fridovich and Handler, 1962).
Human liver aldehyde oxidase has been identified in 
post-mortem human liver (obtained within 4 hours after 
death) by Johns (1967). He also showed that MTX could 
act as a substrate for the enzyme with 7-OHMTX as the 
product (Johns, 1964). Using a method similar to Johns 
(1964), Valerino et al (1972) using DAMPA as substrate, 
produced a product which they suggested may be 7-OHDAMPA.
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Aldehyde oxidase has been purified by homogenising 
the liver in ice-cold water (Hurwitz, 1955; Palmer, 1962; 
Johns and Loo, 1967) or in phosphate buffer (Rajagopalan 
et al, 1962; Johns, 1967) or in Tris buffer (Watson et 
al, 1978) followed by ammonium sulphate precipitation and 
application of the redissolved precipitate to a DEAE 
cellulose or Sephadex G100 column, Watson et al (1978) 
used a crude rabbit liver homogenate to produce 7-OHMTX 
by incubation with MTX standard. The mixture was 
extracted, the residue dissolved in the mobile-phase and 
injected on to an HPLC system. Blank liver homogenates 
were also analysed chromatographically. The chromatogram 
showed poor resolution and interfering peaks were 
present.
AIM
1 , To produce mg amounts of 7-OHMTX for use as a 
standard.
2. To ascertain and confirm the identity of the 
oxidation product of DAMPA (the HPLC method was used 
for process control to follow the conversion of the 
MTX and DAMPA to their hydroxy forms).
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MATERIALS AND EQUIPMENTS
Material
Sephadex G100 was obtained from Pharmacia, Uppsala, 
Sweden and DEAE cellulose obtained from Whatman 
Biochemical Limited, Springfield Hill, Kent. All other 
reagents were obtained from BDH Limited, Poole, Dorset, 
UK or as detailed on page 36.
Apparatus
An ATO mixer was obtained from MSE, England. The 
glass column and fraction collector were obtained from 
Pharmacia, Uppsala, Sweden. The freeze-dryer instrument 
was a 10-148 continuous MRBA type (Techmation Limited, 
London, UK), The HPLC instrument was as previously 
described.
METHODS
Crude Enzyme Preparation
A liver {freshly removed from a New Zealand rabbit) 
was washed first with ice-cold 40 mM Tris hydrochloride 
buffer, pH 7.4 containing 0.2M potassium chloride and 
10 mM magnesium chloride, then intermittently homogenised 
using an ATO mixer with fresh ice-cold buffer (in a ratio 
of 1: 3.25 w/v ) using 5 x 20 second to 30 second
intervals. All equipment was cooled in ice during 
processing. The homogenised liver was centrifuged at 15K 
for 60 minutes at 4"C . The supernatant was removed at 
4^C. This was designated the "crude enzyme preparation".
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Semi-purified Enzyme Fractions
Solid ammonium sulphate was added to the crude 
enzyme preparation at 4°C to give a final concentration 
of 35% w/v. The protein was sedimented by centrifugation 
for 1 hour at 2000 g and, after removal of the 
supernatant fluid, was redissolved in water. Five ml of 
protein solution was applied to a 25 cm x 1 cm ID glass 
column containing Sephadex G100, Forty fractions of 50 
drops each (15 drops - 1 m l ) were eluted by 40 mM Tris 
hydrochloride buffer pH 7.4 containing 10 mM magnesium 
chloride and 200 mM potassium chloride. The fractions 
were monitored by UV absorption at 280 nm and the 
activity of the enzyme in the fractions was then 
determined as described below,
1. Assessment of Enzyme Activity
In order to test the activity of either enzyme 
preparation, 1 ml of solution was incubated at 37 *C for 
10 minutes with 10“ ^M MTX solution. The protein was 
precipitated by heating the mixture in a boiling water 
bath for 5 minutes, centrifuged for 15 seconds at full 
speed on an Eppendorf Microfuge (Surrey, UK) and 20 ul of 
the supernatant applied to the HPLC column.
2. Use of HPLC for Process Control
Samples prepared as described above were analysed 
sequentially until the extent of conversion of substrate 
to product was found to be complete. Drug-free liver 
homogenates were incubated at 37°C for up to 6 hours and
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injected on to HPLC column after deproteinisation. The 
HPLC method was not used for preparative work since the 
final product would be contaminated with ion-pair agents, 
7-OHMTX Synthesis and Purification
Five hundred ml of crude enzyme preparation was 
incubated at 3 7 °C with 100 mg of MTX (4 x 10“^M) for 2 
hours i.e. until complete conversion was observed. The 
percentage conversion of MTX to 7-OHMTX was studied at 30 
minute intervals by HPLC as outlined in Figure 8, until 
conversion of MTX to 7-OHMTX was complete. The whole 
reaction solution was boiled to precipitate the protein, 
centrifuged at 2000 g for 15 minutes and the supernatant 
solution applied to 16 cm x 5.2 cm ID glass column 
containing DEAE cellulose.
0.6M Ammonium bicarbonate was used to elute the MTX 
and 7-OHMTX from the column at room temperature. The 
fractions were collected using a fraction collector set 
at 140 drops/sample and were analysed by both UV 
spectrophotometry (Unicam SP8000 Ultraviolet Recording 
Spectrophotometer, Cambridge, UK) and HPLC.
The fractions containing 7-OHMTX were pooled and 
freeze-dried. The identity of the samples of dried 
material were confirmed using mass spectrometry and 
nuclear magnetic resonance spectroscopy.
MTX (aqueous) e.g. 5 mg.
f r e s h l y  k i l l e d  r a b b i t  l i v e r  h o m o g e n a t e  e . g .  2 0  ml .
( s t o r e d  in i c e  u n t i l  n e e d e d )
3 7 ° C
—  — —  —  -I- 1 ml .  a l i q u o t  e v e r y  1 5  m i n s .
7 - O H M T X  ( 5  a l i q u o t s )
1 0 0 ° C  s p i n  I  | l O O ° C  s p i n
s u p e r n a t a n t  s u p e r n a t a n t
% I
c o l u m n  i n j e c t  ( 2 0  i
| o . e  M N H 4 H C O 3  I
d e t e r m i n e  c o m p l e t e n e s s  o f  r e a c t i o n
c o l l e c t  p u r i f i e d  7 - O H M T X  f r a c t i o n
FIGURE 8 In vitro synttesis ot 7-OHMTX from
MTX using rabbit liver homogenate.
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Synthesis and Purification of 7-OHDAMPA
Three mg DAMPA was dissolved in Tris hydrochloride 
buffer pH 7.4 by adding ammonium hydroxide solution to 
pH 8 to increase the solubility of DAMPA. Five ml of 
crude enzyme preparation was added to the solution and 
incubated at 37°C for 6 hours. A sample was taken at 30 
minute intervals to study the conversion of DAMPA to its 
oxidation product. After 6 hours the reaction was 
completed, and after protein precipitation the 
supernatant solution applied to a 25 cm x 1 cm ID glass 
column packed with DEAE cellulose and eluted by 0 . 6M 
ammonium bicarbonate. Fractions were identified by UV 
absorption at 280 nm.
These fractions were collected, pooled and scanned 
on a UV spectrometer, and submitted to HPLC analysis. The 
pooled fractions were freeze-dried. The product of this 
reaction was studied by both mass spectrometry and 
nuclear magnetic resonance spectroscopy.
Mass Spectral and NMR Analyses
High resolution electron-impact mass spectra were 
obtained with an AE1 MS9 instrument. NMR spectra of MTX 
in deutero methanol (reference standard, TMS ) and DAMPA 
and its metabolite in deuterium oxide containing NaOD 
(reference standard, tertiary butanol, ^  1.23) were 
recorded on a Bruker WM250 spectrometer.
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RESULTS
Crude Enzyme Preparation
There was complete conversion of 10” ^M of MTX 
(2 ul - 50 ug MTX) to 7-OHMTX within 10 minutes. 
Semi-purified Enzyme Fractions
The fractions collected from the Sephadex G100 
column were studied for UV absorbance at 280 nm and 
activity of enzyme (by percentage conversion of MTX to 
7-OHMTX) (Figure 9). From this Figure it can be seen 
that Fraction 15 contained the highest activity.
Synthesis of 7-OHMTX and 7-OHDAMPA
The HPLC chromatogram obtained from a typical 
reaction mixture of the initial (A), intermediate (B) and 
final (C) stages of the reaction are shown in Figure 10 
for conversion of MTX to 7-OHMTX. Similar stages are 
represented in Figure 11 for conversion of DAMPA to 
7-OHDAMPA. From Figures 10 and 11 it can be seen that 
there is complete conversion in each case. The most 
efficient conversions of MTX or DAMPA to their oxidised 
metabolites (100% in 10 minutes) were obtained when the 
starting concentration of MTX or DAMPA in homogenate was 
50 ug/ml (1 x 10“ '^ M or 1.5 x 10”^M respectively). The 
effect of increasing the concentration of substrate was 
shown to result in a lag-phase which was concentration 
dependent. The details for MTX as substrate are shown in 
Figure 12. Samples removed from drug-free liver 
homogenates gave no interfering peaks (Figure 13).
►-----4 Activity
®— -eAbs. at 280 nm
Abs.
100'
50-'
Fractions
FIGURE 9 The UV absorbance at 280 nm and enzyme activity 
(by percentage conversion of MTX to 7-OHMTX) in 
fractions collected from a Sephadex GlOO column.
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FIGURE 12 The effect of MTX concentration on the rate 
of conversion to 7-OHMTX by the crude enzyme 
preparation.
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The use of HPLC as process control allowed a rapid 
optimisation of the biological synthesis of 7-OHMTX and 
7-OHDAMPA.
Identification of Synthesised Products
1. 7-OHMTX
(a) UV spectrophotometry
The elution patterns monitored at 280 nm from the 
DEAE cellulose column are shown in Figure 14 for MTX and 
7-OHMTX. The UV absorbing fractions relating to a single 
peak were pooled and a UV scan performed.
It can be seen that the UV scan for Fraction 100 
(Figure 15) corresponded to that of the MTX standard and 
that the scan of Fraction 270 corresponded to that of 
authentic 7-OHMTX. HPLC analysis confirmed that the k* 
of the isolated compounds corresponded with those of the 
authentic compounds,
2. 7-OHDAMPA
(a) UV spectrophotometry
The elution patterns were monitored as in 1(a) above 
and the elution patterns for DAMPA and '7 - O H D A M P A ' are 
shown in Figure 16. Fraction 20 (Figure 17) was found to 
give an identical UV spectrum to authentic DAMPA. 
Fraction 35 was similar but significantly different with 
a maximium at 340 nm instead of 370 nm. This was assumed 
to be the oxidation product of DAMPA. HPLC analysis
o
V)
<
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400
FIGURE 14 The UV absorbance of fractions from the DEAE 
cellulose column following addition of 
supernatant solution from an incubation of MTX 
with crude enzyme preparation.
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FIGURE 15 UV absorbance spectra of;
1 = Authentic 7-OHMTX
2 = Synthesised 7-OHMTX (fraction 270 from Figure 14)
3 *= Authentic MTX
4 « Eluted MTX (fraction lOO from Figure 14)
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FIGURE 16 UV absorbance of fractions from DEAE chromatography
of supernatant following incubation of DAMPA with 
the crude enzyme preparation.
F 6= fraction number.
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FIGURE 17 UV absorbance spectra of Fractions 20 and
35 (Figure 14) and authentic DAMPA standard 
in O. 6 M ammonium bicarbonate.
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confirmed that fraction 20 co-eluted with DAMPA: Fraction 
35 eluted with a k' = 20.6, this was designated putative 
7 - OHDAMPA. A chromatogram of the isolated compounds is 
shown in Figure 18.
The retention characteristics of putative 7-OHDAMPA 
relative to DAMPA compared with those of 7-OHMTX relative 
to MTX. ;
Fallowing repeated freeze-drying, in order to remove 
ammonium bicarbonate, the final yield of metabolites from 
a complete reaction was approximately 30%. HPLC analysis 
of the supernatant solution, the eluant from the DEAE 
column and redissolved freeze-dried material indicated 
that 90% of losses occurred during the freeze-drying 
process.
(b) NMR and MS Analysis of Freeze-Dried Material
Although MTX did not give a satisfactory mass 
spectrum it was possible to obtain high-resolution mass 
spectra of DAMPA and its metabolite {Table 16) (Figure 
19).
A molecular ion (M+) observed in the mass spectrum 
of DAMPA; m/z 325 (14%) with fragment ions at m/z 176 and 
151. The ion at m/z 176 is ascribed to the 2,4-diamino- 
6-pteridinyl fragment, which results from cleavage of the 
c 9~n 10 bond with hydrogen radical transfer. Similar 
fragmentation pathways were observed for the metabolite 
of DAMPA, with a M"^  ion at m/z 341 and fragment ions at 
m/z 192 and 15 1 . The M"*" ion had a mass 16 amu greater
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than the of DAMPA, which is indicative of the
introduction of oxygen into the molecule, possibly a 
hydroxyl group: That there was an ion at m/z 192 would
indicate that the 2,4 - d iamino-6-pteridinyl moiety had 
been hydroxylated.
Comparison of the NMR spectra of DAMPA and its 
metabolite confirms that the 7-position has been 
hydroxylated (Figure 19), since the signal at S  8.4 
ascribed to the hydrogen at the 7-position is not present 
in the spectrum of the metabolite. The metabolite was 
thus positively identified as 7-OHDAMPA.
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DISCUSSION
The initial supply of 7-OHMTX was only 3 mg (as the 
diammonium salt) and for further studies synthesis of 
more was necessary.
The use of HPLC as process control for monitoring an 
enzyme reaction is a relatively novel approach (Farid et 
al, 1 983b), It has the advantage that there is minimal 
sample preparation, a rapid assessment of reaction 
progress is obtained and only a small volume of the 
preparation is required. Extraction methods cannot 
compare with this. The HPLC method also had the advantage 
that no interfering endogenous peaks were obtained from 
deproteinised incubation mixture, unlike the method of 
Watson et al ( 1978) no artifactual peaks were generated 
during the procedure, and it was applicable to both 
syntheses.
The introduction of an OH grouping into the ring 
results in a shift to the left of the absorption maximum 
at 375 nm to approximately 330 n m . A similar shift 
occurs with the oxidation of DAMPA,
The product of oxidation of MTX has been positively 
identified as 7-OHMTX, confirming the work of Johns et al 
( 1966) .
Valerino et al (1972) oxidised DAMPA and assumed 
that a 7-hydroxyl at ion had taken place, this observation 
has not been re-examined until now. The product of this
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reaction has been positively identified as 7-OHDAMPA 
using both mass spectrometry and nuclear magnetic 
resonance spectroscopy.
CHAPTER 5
CLINICAL STUDIES OF HIGH AND LOW-DOSE METHOTREXATE
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INTRODUCTION
A general review of the pharmacokinetics of MTX was 
given in Chapter 2 for MTX in both high and low doses. 
Some details are extracted here for illustrative 
purposes,
Low-Dose
Low-dose MTX (30 mg/m^) is well absorbed after oral 
administration with a peak serum level appearing after 
1-2 hours. Slow absorption of small doses has been 
noted (Freeman-Narood, 1962). Jacobs et al (1977)
reported that 7-OHMTX was not detected in samples from 
patients on low-dose IV therapy (< 10 mg/kg). However 
Chan et al ( 1 980) reported 7-OHMTX in plasma from these 
patients who were given similar doses.
The cumulative recovery of MTX from urine following 
low-dose (< 30 mg/m^) therapy has been reported as 80% in 
24 hours (Huffman et al 1973).
The half-life of MTX has been investigated by 
several groups. Huffman et al (1973) reported a terminal 
half-life of approximately 27 hours, which conflicts with 
the figure of 2-10 hours reported by others (Henderson et 
al, 1965; Halprin et al, 1971). Lankelma et al (1980) 
reported that the 1 3^ 3 of MTX and 7-OHMTX following an IV 
bolus of 25 mg MTX was 5.5 hours for both, although 
administration of 2,2 mg 7-OHMTX to a normal volunteer 
resulted in a t.3 of 9 hours.
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High-Dose
The percentage absorption of 80 mg/m^ MTX following 
oral administration was estimated as 50-70% (Henderson et 
al, 1965; Wan et al, 1974).
Following high-dose MTX therapy, administered 
intravenously, 7-OHMTX was found to be the major 
metabolite. DAMPA has also been detected in serum and 
urine of some patients treated with high-dose MTX 
infusion (Donehower et al, 1979; Howell et al, 1980).
About 50% of the infused high-dose MTX was recovered 
in urine collected between 6 and 12 hours after the end 
of the infusion (Stoller et al, 1 975 ). Most users of 
HPLC methods (as described in Chapters 2 and 3) did not 
study the pharmacokinetics, an exception being Lankelma 
et al ( 1 980 ). The majority of the pharmacokinetic 
parameters (reported above and in Chapter 2) were 
calculated following analysis using non-specific methods.
The characteristics of the HPLC method used in this 
study (Farid et al, 1983a) have been described earlier. 
The analysis of patients samples using this specific 
method should result in the production of more accurate 
pharmacokinetic parameters.
AIM
1. To determine the plasma pharmacokinetics of MTX in 
high and low-dose,
2. To assess the utility of urinary kinetics in high- 
dose therapy.
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MATERIALS AND METHODS 
Low-Dose Study
Fourteen patients were treated with MTX (15 mg) by 
both oral and IV routes. Seven male and seven female 
patients aged 39-81 years suffering from psoriasis were 
studied. Blood samples were drawn at 0.25, 0.5, 1, 1.5, 
2, 3, 4, 6 and 8 hours after the administration of MTX. 
The plasma was separated and stored at -20 ° C until 
analysed by HPLC.
High-Dose Study
Six patients were treated with high-dose MTX ranging 
from 1.5 gm to 9 gm as an IV infusion. Details of the 
patients and their treatment are shown in Table 17. 
Samples of heparinised blood were collected at 1, 2, 3, 
4, 5, 6, 8, 24 and 30 hours after commencement of the 
infusion. The samples were spun at 1 500 g for 10 
minutes. The plasma was separated and stored at 2 0 “C 
until analysed by HPLC. Urine samples were collected 
every 2 hours for the first day and every 6 hours during 
the second day.
The urine volumes were measured and a 20 ml aliquot 
of each was stored at -20"c for subsequent analysis. 
Analysis
An ion-pair chromatography method as previously 
described (Chapter 3) was used to quantitate the levels 
of MTX and its metabolites in the plasma and urine 
samples.
TABLE 17
The Details of Doses, Courses for Patients 
Treated with High-Dose MTX Therapy________
Patient Dose (gm) Courses
R.M. 9 1
3 3
J.S. 9 1
3 3
D.T. 1.5 2
E.M. 1.5 2
J.M. 1.5 2
L.D. 3.25 1
2.7
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Metabolite Identification
Urine samples in which an unknown peak was detected 
were pooled and stored at -20"C. The samples were loaded 
onto a DEAE cellulose column and eluted with ammonium 
bicarbonate as described in Chapter 4. The appropriate 
fractions were collected, scanned by UV spectrophotometry 
and pooled. They were then freeze-dried overnight. 
Furthep purification was then carried out by recon­
stituting the freeze-dried material in methanol and 
injecting the whole specimen onto an HPLC column in the 
absence of ion-pairing agents, since a metabolite free of 
contamination is required for NMR/MS investigation.
The fractions eluted from the HPLC column were again 
scanned in the UV.
Pharmacokinetic Calculations
1. Low-Dose
The pharmacokinetic parameters were calculated by 
using the following equations:
0.693
t >  =   (1)
' kel
F.D
Vd =   (2)
AUC.kei
F.D
Cl = ------ (3)
AUC
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Where ti = serum elimination half-life
kg% = serum elimination rate constant
Vd - apparent volume of distribution
D = dose
Cl = serum clearance
AUC = area under curve
F = Absorption factor
Half-lives were calculated using a semilogarithmic 
plot of MTX concentration versus t i m e . The area under 
curve (AUC) was calculated using the trapezoidal rule.
MTX bioavailability in patients treated with 15 mg 
MTX either orally or intravenously in alternate weeks was 
calculated as the ratio of the areas under the 
concentration versus time curves for the oral and IV 
doses. The individual F values were taken into account 
when calculating Cl and Vd for the oral data.
2. High-Dose
The pharmacokinetic parameters were calculated as 
described above except that AUC was calculated from the 
cessation of the infusion. In addition they were derived 
from data obtained from analyses of urine specimens, 
employing the following equations:
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Urine conc. x urine vol.
Urine excretion rate = — -------------------------- (4)
Time
Cu X Uf
CIr =   (5)
C«
amount of drug excreted unchanged
fe =---   — ------   (6)
D
CIr
Cl =     (7)
^e
where CI r  = renal clearance
Cu = urine concentration
Uf = urine flowrate
Cg = mid-point serum concentration
fg = fraction of drug excreted unchanged
The renal clearance (CIr ) was calculated, as was the 
fraction of drug excreted unchanged. The total clearance 
Cl was used to assess the utility of urinary kinetics by 
comparison with the plasma data.
The kinetics of 7-OHMTX in plasma were also calcul­
ated using equations 1-3.
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RESULTS
Low-Dose Studies
1. Measurement in biological fluids
A chromatogram obtained from extracts of serum from 
a patient treated with low oral dose MTX at 0.25, and 2 
hours after the dose (15 mg) is shown in Figures 20 and 
21. 7-OHMTX was detected in some but not all patients 
treated with low doses (15 mg).
2. Application and bioavailability
A typical profile of MTX in the serum of a patient 
treated with 15 mg by the oral and IV routes is shown in 
Figure 22.
The bioavailabilities, calculated by comparison of 
AUC (oral) with AUC (IV) gave a range of 17-120% MTX 
absorbed in this group of 14 patients (Table 18), 
although the large AUC for subject A.G. in the IV study 
is not in keeping with the other results.
3. Pharmacokinetic parameters
The calculated pharmacokinetic parameters for MTX 
following low doses administered by either the oral or IV 
routes are illustrated in Table 19. The elimination 
half-lives for MTX following oral and IV routes were 
found to be 2.56±%3 hours and 2.48±0.99 hours 
respectively, these were not significantly different. 
The peak serum levels after oral dose MTX (15 mg) 
appeared at 1-2 hours. There was no intra-individual
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FIGURE 22 Comparison of the plasma MTX profiles following oral
or IV MTX administration at low-dose in one patient.
TABLE 18
The Bioavailability for 14 Patients Treated with 
Low-Dose MTX (15 mg) Orally and Intravenously
Patients Bioavailability
A, G. 17
B. G. 90
A. J. 73
A.W. 120
M. McR. 42
J.D. 17
I.e. 78
J.R. 46
E.T. 55
C.McC. 28
F.W. 89
A.A. 55
S.S. 72
P.S. 70
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variation in clearance but a great deal of inter­
individual variation in both clearance and other 
pharmacokinetic- parameters. 7-OHMTX was detected in all 
samples following oral administration and in 12 samples 
following IV administration but at a later time 
(p < 0.05, sign test).
High-Dose Study
1 Measurement in biological fluid
Representative chromatograms obtained from extracts 
of serum from a patient treated with high-dose MTX and a 
subject taking no known medication are shown in Figure 
23.
The chromatograms of the equivalent urines are shown 
in Figures 24a and 24b respectively. The blanks are 
clear with no endogenous interference.
2. Presence of MTX metabolites
MTX, 7-OHMTX, DAMPA, 7-OHDAMPA were detected in the 
urine while only MTX, 7-OHMTX and DAMPA were detected in 
plasma.
DAMPA was found in 3 out of 6 patients treated with 
high-dose MTX in plasma and urine but was not present 
during every infusion.
The chromatograms obtained from serum extracts of 
'early' and 'late' samples from a patient treated with a 
3 gm MTX infusion are shown in Figure 25. The early 
sample was taken during the infusion; the MTX concen­
tration can be seen to be higher than 7-OHMTX as
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FIGURE 23 Chromatograms of serum extracts from two patients
a) Following MTX therapy with 1 g IV bolus 
followed by 2 g over 24 hours.
b) Drug-free subject.
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FIGURE 25 Chromatograms of serum extracts from a subject 
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expected. The late sample was taken at 6 hours after 
completion of the infusion, at which time the 7-OHMTX 
concentration was higher than that of MTX.
3. Application
The elimination of MTX and the rise and fall of 
7-OHMTX following high-dose MTX by IV infusion is shown 
in Figure 26. The concentrations of 7-OHMTX were greater 
than those of MTX 13 hours after the dose.
I
The corresponding urinary time curve is shown in 
Figure 27. The time points represent the mid-point of 
each collection. There was a consistent decline in MTX 
concentration from 4 hours after starting this infusion. 
The appearance of 7-OHMTX is rapid although the concen­
tration found fluctuated from collection to collection 
and may be related to intermittent alkalinisation. The 
pH of these urine samples was not measured.
4. The concentration of the MTX metabolites during
and after sequential infusion
The concentration of MTX and its metabolites in the 
plasma and urine during and after 3 serial infusions with 
the same dose of MTX (3 gm) were studied in 2 patients. 
The plasma profiles following the high-dose infusion in 
one patient (R.M.) are shown in Figure 28. There was a 
significant increase (p < 0.001, t test) in the concen­
tration of 7-OHMTX between the first and third infusions. 
DAMPA was found in the second and third courses.
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FXGURE 26 Serum concentrations of MTX and 7-OHMTX
following a dose of 9 gm MTX (IV) over 
6 hours.
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FIGURE 27 Urine concentration of MTX and 7-OHMTX following
a dose of 9 gm MTX (IV) over 6 hours. The points 
represent the mid-point of collection.
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FIGURE 28 Serum concentration of MTX and its metabolites following 
3 serial infusions in one patient treated with 3 gm MTX 
infusion over 6 hours.
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The cumulative urine profiles following the 
high-dose infusions are shown in Figure 29. There was an 
apparent decrease in the 7-OHMTX excretion between the 
first and third infusion (p < 0.001, t test), DAMPA and 
7-OHDAMPA were found during and following the third 
course.
Two serial infusions with 3.25 gm and 2.7 gm over 6 
and 5.5 hours respectively were studied in a third 
patient (L.D.). The resultant plasma profiles are shown 
in Figure 30 for the first course and Figure 31 for the 
second course. Both 7-OHMTX and DAMPA are present on 
both occasions.
5. MTX excretion in urine
The mean percentage of a dose of MTX excreted in the 
urine in 24 hours (Jhl SD) versus the MTX dose is shown in 
Figure 32, where it can be seen that the percentage of 
MTX excreted decreases as the dose increases.
6. Pharmacokinetic parameters
The pharmacokinetic parameters for MTX and 7-OHMTX 
following high-dose MTX infusion are presented in Table 
20. These were calculated using both plasma and urine 
data and the clearances were comparable. Due to problems 
in obtaining full sets of samples, plasma data were 
only obtained from four courses. Two complete urine 
collections were obtained.
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FIGURE 29 Cumulative urine excretion of MTX, 7-OHMTX,
DAMPA and 7-OHDAMPA in 3 serial infusions in 
one patient treated with 3 gm MTX IV over 6 
hours.
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The AUC for 7-OHMTX increases with subsequent 
courses of treatment. The AUC for MTX is not clearly 
increased. The clearance of 7-OHMTX also declines and is 
related to a measured fall in creatinine clearance.
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DISCUSSION
The results obtained above represent the first 
investigations of MTX pharmacokinetics using a highly 
specific method. The low-dose studies were undertaken in 
order to look at the effect of bioavailability in 
patients receiving MTX for psoriasis. These studies had 
not been made before since the readily available EMIT 
assays I were not sufficiently sensitive at the levels 
expected (v-^10"^M).
The wide range in bioavailability found (17-120%) 
was surprising, even accepting a proportion of error as 
demonstrated by the figure of 120% in one patient, and is 
due to a true difference in absorption of the drug, since 
each subject acted as his or her own control. There was 
no ready explanation for the AUC observed for subject 
A.G. in the IV study, but adoption of these values
results in the calculation of a low V^. In the absence of
evidence to the contrary all values obtained were assumed 
to be correct.
From Table 19 it may also be seen that, even
allowing for 7-fold differences in absorption, there is a 
considerable inter-subject variation of the clearance of 
MTX; clearances may vary by as much as a factor of 1Ü . 
These results are confirmed by the remarkable
reproducibility of clearance regardless of whether the 
MTX was given orally or by IV.
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The problems of bioavailability therefore may be 
overcome by intravenous administration of MTX, however 
there still remains a large inter-subject variability, 
sufficient to cause wide differences in plasma 
concentration in patients receiving the same dosage.
These results confirm that for the effective 
achievement of reproducible plasma levels of MTX in 
patients receiving low-dose MTX, plasma concentrations 
may require to be monitored. This is particularly so 
since MTX is well recognised as compromising liver 
function as well as renal function after repeated 
administration.
The studies also showed that 7-OHMTX appeared in the 
plasma earlier and at higher concentrations following 
oral dosing than when MTX was given intravenously. 
Although the evidence is insufficient to prove it, this 
suggests that there may well be an element of first pass 
metabolism for MTX. If so, this would be the first 
demonstration of a first pass effect for a drug mediated 
by hepatic aldehyde oxidase, rather than the better 
understood microsomal P450 oxidation system.
7-OHMTX was also detected at 30 minutes after the 
initiation of high-dose intravenous MTX infusion 
confirming the findings of Collier et al ( 1982 ). This 
finding does not argue against the first pass effect 
proposed above. Within 30 minutes, 250 mg MTX would have 
been infused, assuming a hepatic extraction ratio of 0.1
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and a hepatic clearance of 4 litres/hour; thus approx­
imately 12 mg MTX would be converted to 7-OHMTX in this 
time; assuming distribution only in the plasma water, and 
assuming no renal clearance, then a concentration of 
3.5 mg/1 7-OHMTX might be expected. Taking into account 
renal clearance and distribution this figure is 
considerably lower (V^ - 200 litre, CIr = 3 litre/hour) 
i.e. 12 ug/1 (v/^2 x 10” ^M). The concentrations at 30 
minutes are of this order of magnitude.
DAMPA is detectable using this system following 
high-dose therapy, despite the fact that its plasma 
concentrations are two orders of magnitude less than MTX. 
The source of DAMPA has been suggested as either 
deg lu tarnation of MTX by entrobacter ia (Donehower et al, 
1 979 ) or as a contaminant in the infusion fluid 
(Chatter]i et al, 1978).
DAMPA was observed in some patients during some 
courses of treatment, but this was not a reproducible 
finding. The number of data points obtained were 
insufficient to calculate kinetics. However, the fact 
that the plasma levels fell steeply in each case from the 
end of the infusion suggests that the source is indeed 
contamination of the infusion fluid, since production in 
vivo, especially by a route which would necessitate 
absorption from the gastrointestinal tract would give a 
curve which would have an initially rising component.
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It was unfortunately not possible to obtain samples 
of the infusion fluids used in these courses in which 
DAMPA was detected. Twelve samples of infusion fluid 
examined prospectively contained no detectable DAMPA.
In urine samples obtained from patients with DAMPA 
in the plasma, a peak which co-eluted with 7-OHDAMPA, 
synthesised as in Chapter 4, was obtained. Attempts were 
made to collect and positively identify this component, 
however, insufficient was obtained for NMR analysis and 
the fragmentation pattern obtained using EI/MS was 
equivocal. It is possible that MS using chemical 
ionisation may give a final answer to this question. The 
metabolite did, however, show a UV spectra identical to 
that of authenticated 7-OHDAMPA.
The high-dose studies confirm the predominant 
influence of renal clearance on the removal of MTX from 
plasma. In Table 20, the serial results for patient R.M. 
indicate that a reduction in creatinine clearance is 
reflected in reduced MTX renal clearance. The effect on 
the area under the plasma MTX concentration curve is less 
marked. The hepatic clearance did not change
significantly between serial courses of treatment.
7-OHMTX concentrations showed substantial increases 
in AUC in sequential courses of treatment in subject R.M. 
This could be related to the reduced renal clearance, but 
could also be due, in part, to increased conversion of 
MTX to 7-OHMTX due to induction. It should be noted that
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induction of aldehyde oxidase activity has not been 
documented. There was, however, little observed fall in 
MTX concentrations which would be expected were induction 
to contribute a significant part to these findings. R.M. 
showed a fall in creatinine clearance of 70-50 ml/minute 
which could account for all of the accumulation of 
7-OHMTX in this patient. 7-OHMTX is less soluble than 
MTX and the association noted by Link et al (1976) of 
reduced creatinine clearance and MTX induced renal 
toxicity could be the result of this.
7-OHMTX is less water soluble than MTX and is 
therefore also nephrotoxic. In each of the high-dose 
studies the concentration of 7-OHMTX exceeds that of MTX 
after 13 hours post infusion. This suggests that in 
cases where renal function is borderline it may be useful 
to measure this metabolite as well as MTX in an effort to 
determine the optimum therapy for the avoidance of renal 
damage.
The kinetics of MTX were calculated using both 
plasma and renal concentration data in order to study the 
possibility of using the non-invas ive method. The 
similarity of the results obtained using the two methods 
(Table 20) means that urinary studies may be used for the 
calculation of total clearance and other parameters.
89
In particular the figures obtained for R.M. showed 
that the renal clearance decreased during the course of 
three infusions, whereas non-renal (mainly hepatic) 
clearance was unchanged.
In the low-dose study it was noted that there was 
wide inter-individual variation in MTX handling. Mojalano 
et al (1979) have suggested that a low-dose study should 
therefore be used in order to assess the dose required 
for high-dose therapy. However, a comparison of the low 
and high-dose kinetics shows that there was a significant 
increase in t^ g in the high-dose patients over those 
receiving low doses, of the order of 5 to 10-fold.
The dose-related excretion of MTX, with a lower 
proportion of the dose excreted at high doses holds, 
whether or not 7-OHMTX is added. So far as is known this 
fact has not been highlighted before.
Following high doses, higher volumes of distribution 
were observed. Part of this in patient L.D. can be 
related to the presence of a third space in the form of a 
pleural effusion, and was probably also the case with 
R . M .
At low doses there is saturation of the primary 
intracellular binding sites (thought to be in part DHFR) 
which is overcome by less selective binding at higher 
doses (Dedrick, Zaharko and Lutz, 1973). These facts 
could account for the differences in calculated 
parameters.
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In view of the variability in the pharmacokinetics 
in the studies of both high and low-dose M T X , the 
significantly lower solubilities of the MTX metabolites 
and the implications of this for patients, it may be 
necessary not only to follow the concentration of MTX 
during high-dose therapy but also to determine 7-OHMTX.
MTX plasma concentrations during low-dose therapy 
may also be of assistance in optimising oral dosage.
CHAPTER 6
IN VITRO STUDIES OF THE INTERACTIONS BETWEEN METHOTREXATE 
AND BACTERIAL AND HUMAN CULTURED CELLS
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INTRODUCTION
Bacteria
A loss in biological activity of MTX after its 
contact with several kinds of bacteria was first reported 
by Webb (1955). Levy and Goldman (1967) reported the 
conversion of MTX to its deglutamated metabolite, DAMPA, 
using pseudomonads isolated from soil. This metabolite 
has also been detected in man, and it has been suggested 
that it might be produced in the intestine by the action 
of bacterial carboxypeptidase (Donehower et al, 1979).
Zaharko, Bruckner and Oliverio (1969) reported that 
in the mouse and rat significant amounts of previously 
undetected MTX metabolite were present in urine and 
faeces after intraperitoneal administration of the 
tritium-labelled MTX. The production of this metabolite 
was significantly less in germ-free mice and also in mice 
which had been pretreated with antibiotics, it was 
suggested therefore that intestinal bacteria were 
responsible for the conversion. Valerino et al (1972) 
identified the metabolite as DAMPA. There are no reports 
of studies on intracellular metabolites in bacteria.
Human Culture Cell Lines
The metabolites of MTX inside a variety of cultured 
cells have been studied. Rosenblatt et al ( 1 978 ) 
reported the presence of MTXC^ and M T X G 2 in cultured 
human fibroblasts. These metabolites were identified and 
eluted from Sephadex G15.
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Whitehead (1977) synthesised the MTX polyglutamates 
in L1210 murine leukaemia cells and used Sephadex G15 for 
eluting those metabolites, Gewirtz et al (197.9) used 
DEAE cellulose to identify the MTX polyglutamates in rat 
hepatocyt e s . Most of the authors used labelled MTX for 
their studies. In this work, the effect on MTX of 
several species of enterobacteria and a group of cultured 
cell lines was studied by analysing both the supernatant 
medium and the cytoplasm using the HPLC method previously 
described (Chapter 3).
MATERIALS AND METHOD 
Bacteria
The strains were grown in Mueller-Hinton broth. 
These bacteria strains were: Citrobacter Freund i i , 
Klebsiella Pneumoniae, Pseudomonas Aeruginosa, Acineto- 
bacter Calcoacetius (Var. Anitratrium), Escherichia Coli 
(E. Coli), Klebsiella spp and Pseudomonas spp.
The bacterial cultures were incubated in broth with 
different concentrations of MTX (10"^M, 10”^M and 10“"^M). 
Blank samples were obtained from cultures containing no 
MTX. After incubation for 24 hours the tubes were
centrifuged at 1500 g to sediment the bacteria and the 
supernatant broth stored at - 2 0 *C until analysed. The 
bacterial pellets were washed twice with normal saline 
and stored at -20 ''C.
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1 . Supernatant
One ml of supernatant broth was heated in a boiling 
water bath for 5 minutes. Following centrifugation, 
20 ul of the clear supernatant was injected onto the HPLC 
column using the HPLC method previously described 
(Chapter 3).
2, Bacterial Pellets
The residue was resuspended in 10 ml distilled water 
and sonicated using an ultrasonic probe for 10 minutes. 
The solution was cooled in ice during sonication. The 
pH of the solution was adjusted to pH8 using potassium 
carbonate solution and then applied slowly to a column of 
Dowex 1-x2 (2 cm in height). One hundred ug of L-trypto- 
phyl L-glutamic acid (internal standard) was mixed with 
the solution before application to the resin.
Four ml of methanol was used to wash the resin and 
the eluant was discarded. MTX and its metabolites were 
eluted using 2 ml of 5% acetic acid in methanol and 4 ml 
of 25% acetic acid in methanol. The acidic fractions 
were collected and were evaporated to dryness using the 
rotary evaporation vacuum pump. The residue was 
dissolved in 100 ul mobile-phase and 20 ul was injected 
onto the HPLC column.
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Cells
A variety of human melanoma and choriocarcinoma 
cells (Table 21) were grown in culture medium containing 
different concentrations of MTX or 7-OHMTX by Gaukrodger 
et al ( 1 983 ). The details of the procedure were as 
follows.
The cells were grown in r p m I ‘ 1 640 medium
supplemented with 10% v/v newborn calf serum (Flow 
Laboratories, Irvine, Scotland). Different batches of 
serum containing folate at concentrations ranging between 
25-53 nM were u s e d . Incubation was carried out at 
37*C in a humidified atmosphere of 5% C02/95% air. The 
density of the cells was 5 x 10^ cells per 25 cm^ tissue 
culture flank. The tissue cultures were inoculated in 
duplicate with MTX or 7-OHMTX at concentrations of
I  X l O - ^ M .
Samples from cultures were taken after 36 hours and
II days for HPLC analysis The incubation samples were 
centrifuged and the cells were separated from the 
supernatant. The cells were washed twice in serum-free 
medium and then suspended in 1 ml distilled water and 
ruptured using an ultrasonic probe for 20 seconds.
TABLE 21
Human Melanoma and Choriocarcinoma Cells Studied
Human Melanoma B8 
BIO 
MEL 57 
MYJ 15 
ADLER 
Kotier
Murine Melanoma PG 19
Human Choriocarcinoma BeWO
JAR
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1 . Supernatant from cell cultures
The supernatant was boiled in a heated water bath 
for 10 minutes to precipitate the protein. Following 
centrifugation, 20 ul of clear supernatant was injected 
onto HPLC using the method previously described in 
Chapter 3.
2. Cell pellets
Following rupture of the pellets, the solution 
was extracted using the anion-exchange resin with 
L-tryptophyl L-glutamic acid as internal standard. The 
residue was dissolved in 50 ul mobile-phase and 20 ul was 
injected onto the HPLC column using the same method as 
previously described in Chapter 3.
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RESULTS
Bacteria
1. Supernatant broth
There were no significant changes in MTX observed in any 
of the broth samples. DAMPA was the only metabolite that 
was expected (Donehower et al, 1979), but it seems that 
none of the bacteria that were used in this protocol were 
capable of forming DAMPA in vitro.
2. Bacterial pellets
Chromatograms of the extract obtained from one 
strain of E. Coli after incubation with different 
concentrations of MTX (10“ ^M and 10” ^M) is shown in 
Figure 33a, b. It can be seen a peak with an identical 
elution to MTX triglutamate (MTXG 2 ) was found in each 
case. The chromatograms obtained from other bacterial 
species showed no formation of such a metabolite. An 
example is shown in Figure 34.
Cells
1. Supernatant from cell cultures
The supernatant culture media from cells incubated 
alone, or treated with either MTX or 7-OHMTX for 7 days 
or 11 days were analysed by HPLC. Incubation was 
continued to 11 days in order to investigate a possible 
relationship between cell lysis and MTX metabolism. No 
correlation was found.
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FIGURE 33 Chromatogram obtained from an extract of 
culture medium when E, Coli was incubated 
with (a) lo"^M MTX and (b) MTX.
Peak identities are:
1 *= Internal standard
2 6= MTX triglutamate (G^)
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FIGURE 34 A chromatogram obtained from the culture
medium following incubation of pseudomonas 
aeuroginosa with MTX showing no formation 
of MTXG^.
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Representative chromatograms obtained at 11 days 
from PG19 cells which metabolise both MTX and 7-OHMTX, 
and from BIO cells which metabolise neither compound are 
shown in Figures 35a, b. In each experiment chromato­
grams from 'control* cultures, incubated for the same 
time intervals in the absence of MTX and 7-OHMTX showed 
only the peak marked *M*. In each case the baseline was 
flat in the area of the metabolite peaks, at a detector 
sensitivity of 0.08 AUFS. Supplementation of culture 
extracts with MTX or 7-OHMTX immediately prior to HPLC 
gave peaks eluting in the region of the profile assigned 
to the pure compound.
These studies showed that some of the melanomas 
appeared to metabolise added MTX. The findings are
summarised in Table 22.
In the PG19 cultures the metabolites appeared either 
as a shoulder on the main MTX peak or as additional peaks 
in the optically active material eluting early from the 
column (Figure 35a). These peaks do not correspond 
to any of the known metabolites. They did not co­
chromatograph with polyglutamyl derivatives of MTX. The 
patterns were reproducible within cell lines. Studies 
with 7-OHMTX show that this was more stable in the 
cultures and as can be seen from Figure 35a did not yield 
the same metabolite profiles as MTX.
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FIGURE 3 5a HPLC profiles obtained from culture medium 11 days
after incubation of PG19 cells in the presence of 
10 M  MTX or 7-OHMTX.
M = substance present in medium
. A,B,C = unknown metabolites
Position of MTX and 7-OHMTX shown dotted. Control 
cultures showed only peak M.
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FIGURE 3 5b HPLC profiles obtained from culture media 11 days 
after incubation of BlO cells in the presence of 
lO M MTX or 7-OHMTX,
M  ” substance present in medium 
A,B,C = unknown metabolite
Position of MTX and 7-OHMTX shown dotted. Control 
cultures showed only peak M,
TABLE 22
Summary of HPLC Analyses of MTX and 7-OHMTX Metabolism 
in vitro by Different Cell Lines________________
LINE MTX 7-OHMTX
Medium alone No change No change
Murine melanoma 
PG 19 Altered Altered
Choriocarcinoma
BeWo
JaR
No change 
No change
Altered 
No change
Human melanoma 
ADLER 
MYJ 15 
KOT 
B8 
BIO 
MEL 57
No change 
No change 
No change 
Altered 
No change 
No change
Altered 
Altered 
Altered 
No change 
No cha nge 
No change
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2. Cell pellets
The pellet extracts injected onto HPLC showed no 
peak except the internal standard.
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DISCUSSION
From the results of the bacterial experiments, we 
have confirmed that MTX passes into the cells in all 
species. No DAMPA or 7-OHMTX was detected either in the 
bacterial pellets or the supernatant broth. These 
studies therefore confirm that, at least in vitro, none 
of these 19 strains of gastrointestinal bacteria are able 
to deg^utamate MTX in vitro.
In only one strain of E. Coli was a significant 
amount of a putative metabolite found in the pellet 
extract. There was insufficient of this preparation to 
allow definitive identification, however the 'metabolite' 
co-eluted with MT X G 2 and it is not inconceivable that 
this could be its true identity.
It has therefore been impossible to add to the 
observations of Levy and Goldman (1967) who reported the 
conversion of MTX to DAMPA by pseudomonas spp isolated 
from soil.
Using tracer MTX, Jolivet and Schilsky (1981) found 
MTX diglutamate and triglutamate in cultured human breast 
cancer cells. These metabolites were fractionated by HPLC 
and each fraction was counted by liquid scintillation 
counting. After fractionation of the same sample using 
Sephadex G15, they identified only the diglutamate and 
not the triglutamate. Using this HPLC method and UV 
detection, MTXGg was not detected in the cell pellets 
which were studied. It is probable that, with the small
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numbers of cells available, the sensitivity of the 
HPLC/UV method is insufficient. However the failure to 
detect intracellular metabolites could be attributed to 
the conditions used since Rosenblatt et al (1978) 
reported that the accumulation of polyglutamate by the 
cells was dependent on the concentration of MTX in the 
culture medium, duration of incubation and stage of the 
culture cycle.
Studies on the culture broth in which human cell 
lines were incubated in the presence of MTX and 7-OHMTX 
produced different results, depending upon the cell lines 
employed. The PG19 (murine melanoma) strain is known to 
be MTX sensitive in v i t r o . This strain gave rise to 
changes in the pattern of MTX and 7-OHMTX in the culture 
medium, despite the fact that the majority of cells were 
killed within 48 hours of incubation. The peaks 
obtained, were again, not identified however one of the 
peaks in Figure 35a elutes at a retention volume 
identical to MTX in a culture to which only 7-OHMTX had 
been added, and raises the possibility that this line may 
be able to convert 7-OHMTX to MTX.
The BIO cells originate in a human melanoma cell 
line sensitive to MTX in vitro but resistant in vivo. It 
is of interest that these cultures showed only MTX or 
7-OHMTX at the end of 11 days, with no other peaks in the 
chromatogram. These results were found to be re­
producible in subsequent cultures of these cell lines.
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One of the suggestions for the failure of MTX 
therapy in vivo against cells known to be sensitive in 
vitro is that the MTX is metabolised differently in these 
two environments. These studies show that cell-kill in 
vitro does not seem to be related to the 'metabolism' of 
MTX or its major metabolite.
The majority of cell lines studied alter 7-OHMTX as 
judged by HPLC analyses of supernatant broth. Less lines 
affect MTX itself. Once again there appears to be no 
relationship between susceptibility to the d r u g (s ) and 
its removal from the culture medium. Detailed studies in 
MTX uptake and the effect of leucovorin-rescue in vitro 
on cell-kill by both MTX and 7-OHMTX have been reported 
elsewhere (Gaukrodger et al, 1983).
CHAPTER 7
DEVELOPMENT AND APPLICATIONS OF AN ASSAY FOR THE 
DETERMINATION OF ANTHRACYCLINES IN BIOLOGICAL FLUIDS
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INTRODUCTION
Structure
The anthracycline antibiotics doxorubicin, 
(adriamycin (ADR)) and daunorubicin (daunomycin (D A U N )) 
are important anti-neoplastic agents. The anthracyclines 
are derived from fermentation products of the fungus 
streptomyces peucetius (var. caesius).
Tlfie general structure of the anthracycl ines is shown 
in Figure 36, Both compounds have tetracyclic ring 
structures with an unusual sugar, daunosamine, attached 
by a glycos id ic linkage. ADR differs from DAUN by an 
hydroxyl group at C-14.
Mechanism of Action and Usage
The mechanism of action of the anthracycl ines has 
been inferred from their ability to bind specifically to 
DNA by intercalation between adjacent base pairs, thus 
inhibiting DNA synthesis (Gabbay et al, 1976). Inhibition 
by ADR of DNA, RNA and protein synthesis has been 
documented in both cell-free systems and intact cells 
(Momparler et al, 1976). Furthermore, a recent study has 
shown that ADR will inhibit DNA polymerase in vitro, 
both competitively and non-competitively, and that the 
amino-sugar is critical for the ionic binding of 
anthracycl ines to single-stranded DNA (Goodman, Lee and 
Bachur,1977).
o  OH
O H  HOCH
H O
HNH
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Doxorubicin 
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R
O
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o
— C  — C H 3
FIGURE 36 The structures of Doxorubicin (ADR) and
Daunorubicin (DAUN).
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ADR is used against both primary and metastatic 
tumours (Gottlieb and Hilly 1974; Haskell, Eilber and 
Morton, 1975; Kraybill et al, 1977) while the clinical 
usefulness of DAUN is principally confined to the 
treatment of acute leukaemia in adults.
Dosage
The currently recommended dose of ADR is 60-75 mg/m% 
administered as a single rapid intravenous infusion and 
repeated after 21 days. The drug has also been given in 
doses of 0.5-1 mg/kg daily for 2-6 days or in doses of
20-30 mg/m^ daily for 3 days or once weekly.
The recommended dose for DAUN is 30-60 mg/m^ daily
for 3 days or once weekly. The drug has also been given
in doses of 0.8-1 mg/kg daily for 3-6 days (Calabresi and 
Parks, 1980 ) .
Toxic Effects and Side Effects
The main toxic effects of ADR are as follows:
1. Cardiotoxicity
The most comprehensive information was collected in 
clinical studies of 1273 patients in a trial of ADR 
treatment carried out in 12 European Cancer Centres 
(Praga et al, 1979). The mean total dose of ADR was 
268 m g / m ^  (range 15-1251 m g / m ^ ). The significant 
occurrence of cardiotoxicity is related to the total dose 
of ADR. There is an additional incidence of toxicity when 
vincristine is given either before, or concurrently, with 
ADR and with therapeutic regimes in which bleomycin is
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given before ADR, Radiotherapy to the mediastinum, when 
given along with ADR, also gives rise to an increase in 
the incidence of cardiotoxicity. None of the 182 
patients receiving ADR by slow infusion developed such 
toxicity. This was confirmed by Legha et al (1982).
Although the heart failure can be controlled by 
conventional treatment, death from side effects has been 
reported in 33-75% of patients v/ho developed it (Lenaz 
and Page, 1976; Lefrak et al, 1973; Minow et al, 1977). A 
clear relationship exists between the cumulative dose of 
either drug and the incidence of congestive heart 
failure. Below a cumulative dose of 550 mg/m^ of ADR , 
the incidence of congestive heart failure is less than 1% 
(Lenaz and Page, 1 976; Lefrak et al, 1 973 ). The 
incidence rises sharply with doses above 550 mg/m^ 
affecting 30% of patients so treated (Lefrak et al, 1973; 
Lenaz and Page, 1 976 ). Couch, L o h , Sugino (1981 ) 
reported sudden cardiac death of an 18-year old man 
following ADR therapy (8 months after the last dose of 
ADR) .
2. Bone marrow depression
The depression of bone marrow function is associated 
with myelosuppression (Benjamin, Wiernik and Bachur,
1974). Thrombocytopaenia can also be troublesome 
particularly in patients who have received prior
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radiation to the marrow, have bone marrow métastasés, or 
who have compromised hepatic function (Benjamin et al,
1975).
Kelsen and Yagoda (1980) reported that the platelet 
count decreases before the white blood cell count and 
both reach nadir within 7-14 days, but usually return to 
pretreatment levels within 21 days after initiation of 
therapy.
3. Stomatitis
The most common toxic effect on the mucosa is 
stomatitis. Oral ulceration and occasional oesophageal 
lesions are seen with ADR administration, this is also 
dose-dependent (Kelsen and Yagoda, 1 980 ). Lesser side 
effects are vomiting, nausea, alopecia, fever, chills, 
flushing and drowsiness (Benjamin et al, 1975; Kelsen and 
Yagoda, 1980).
Metabolism of Doxorubicin
The first step in the metabolism of ADR is carboxyl 
reduction at the C-14 position to doxorubicinol (ADRol). 
The small structural change does not prevent ADRol from 
binding to DNA and therefore this metabolite is thera­
peutically active (Bachur, 1976). The enzyme responsible 
is thought to be an aldo-keto reductase which has a 
ubiquitous distribution throughout the body tissue 
(Bachur, 1976).
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There is considerable between-species variation in 
the proportion of parent drug metabolised to A D R o l . Man 
is intermediate (Glode et al, 1977 ) between the highest 
reported rate which is found in the rabbit (Bachur, 
Hildebrand and Jaenke, 1974) and the lowest reported rate 
which is found in the rat (Tavoloni and Guarino, 1980). 
The further biotransformation of ADR and ADRol has 
principally been determined by Takanashi and Bachur
(1976) as shown in Figure 37.
Cleavage of both ADR and ADRol at the glycosidic 
bond results in formation of the respective aglycones. 
Both are relatively insoluble in water and require 
conjugation to either sulphate or glucuronic acid before 
excretion. Both of these conjugated metabolites have 
been identified in rabbit and human bile (Bachur et al, 
1974; Riggs et al, 1977). Further degradation includes 
demethyl ation and a variety of other metabolites have 
been identified in urine (Takanashi and Bachur, 1976) 
using thin-layer chromatography.
The aglycone and conjugated metabolites are thera­
peutically inactive but their contributions to the 
toxicity of ADR is unknown.
Methods of Assay
ADR and its metabolites have been determined by 
several different assay methods.
5«
1-Doxorubicin
2 -  Doxorubiclnot
3-Doxorublcln Aglycone
4-Doxorubicinol Aglycone
5-Oeoxydoxorubicin Aglycone
6-Deoxydoxorubtcinol Aglycone
7-Oemethytdeoxydoxorublcinol 
Aglycone
6-Demathyldeoxydoxorubicinol 
Aglycone 4-0-sulphato 
8 -  Dom ethyldeoxydoxorubicinol 
Aglycone 4-0-B-Glucuronide
FIGURE 37 The metabolic pathway for Doxorubicin
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1. Fluorimetric
Huffman, Benjamin and Bachur (1972) reported a 
fluorimetric method for the measurement of total ADR. The 
serum was mixed with 75% ethanol - 0.45 N hydrochloric 
acid and the resulting fluorescence was measured 
directly. This method is not specific due to cross­
reaction by both metabolites and endogenous fluorophores.
2. Radioimmunoassay
Vunakis et al ( 1 974) developed a radioimmunoassay 
for the measurement of ADR, Antibodies have been 
produced in rabbits, monkeys and goat by immunization 
with ADR-prote in conjugation. The sensitivity of the 
method was 2 pmols/ml (1 n g / m l ). It is somewhat non­
specific due to interference by ADR aglycone (ADRone) 
(25%).
3. Thin-layer chromatography
Takanashi and Bachur (1976) reported a TLC method 
for the separation of ADR and its metabolites from urine. 
Quantitation was achieved by elution of the relevant 
areas and measurement of fluorescence or by the use of 
fluorescent scanners (Watson and Chan, 1976),
The TLC method is simple, rapid, and can give 
quantitative results. Until 1980, the majority of 
clinical studies have relied on this method for the 
analyses. However,the efficiency of chromatography in 
published reports is such that overlap of active and 
inactive metabolites occurs. There is now also a fair
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amount of evidence that many of the metabolites are a 
result of degradation of ADR and its metabolites on the 
TLC plates (Poochikian, Cradock and Flora, 1981).
4. High performance liquid chromatography (HPLC)
Several methods have been published. All used a 
solvent extraction procedure. Solvents used include 
chloroform : isopropanol (Andrews et al, 1980; Pierce and 
Jatlow^ 1 979 ) and chloroform : methanol (Baurain et al, 
1979; Strauss et al, 1980; Shinozawa, 1980).
Sepaniak and Yeung (1980) reported an HPLC method 
employing direct injection of urine samples. The method 
of Barth and Conner (1977) was applied only to 
pharmaceutical preparations and no extraction procedure 
was employed.
Normal-phase columns were used by Barth and Conner
(1977), Baurain et al (1979) and Shinozawa (1980). 
Reverse-phase columns have been used by Pierce and Jatlow
(1979), Andrews et al (1980) and Sepaniak and Yeung
(1980) .
Most of the authors used fluorescence detectors. UV 
detection was found to be sufficiently sensitive for the 
analysis of pharmaceutical preparations (Barth and 
Conner, 1977). Reported recoveries of ADR ranged from 
65-99.7%, The sensitivity of such methods is high, 
ranging from 1,5-25 pmol/ml (0.8-13.6 ug/1). None of the 
authors reported studies of the possible interference by 
other anti-neoplastic drugs. This is surprising in view
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of the fact that ADR is seldom used alone in treatment 
regimes. A summary of the details of extraction 
solvents, m o b i l e - p h a s e , packing materials, recovery 
precision, sensitivity, linearity and drugs interference 
is shown in Table 23,
Aims
The aims of this study were:
1. TOI develop an accurate, rapid, precise and sensitive 
method for ADR and its metabolites.
2. To investigate the effects of ion-pair agents on the 
chromatography.
3. To apply the method to clinical samples.
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MATERIALS AND METHODS
Doxorubicin (ADR), Doxorubicinol (ADRol), Doxo­
rubicin aglycone (ADRone) and Daunorubicin (DAUN) were a 
gift from Farmitalia (Milan, Italy). Pentanesulphonic 
acid, hexanesulphonic acid, heptanesulphonic acid, 
octanesulphonic acid, tetraethy 1 ammonium bromide, and 
dodecyltrimethylammoniura bromide were Fisons HPLC grade 
(Fison, Scientific Apparatus, Longborough, England). 
Sodium dihydrogen phosphate was obtained from BDH. 
Solvents were HPLC grade and obtained from Rathburn 
Chemicals (Walkerburn, Peebleshire, Scotland). All other 
reagents were Analar grade and obtained from British Drug 
Houses (Poole, Dorset, England). Brij 35 was obtained 
from Technicon Chemical Co. (Hamilton Close, Basingstoke, 
Hants, England).
Apparatus
A Pye-Unicam HPLC system (Cambridge, England) 
consisting of an LC-XPS single piston reciprocating pump, 
a PM8251 single pen recorder and LC-FL detector with 
interference filters at 450 and 550 nm for the excitation 
and emission wavelengths respectively, were used.
The column (10 cm x 5 mm ID) (Shandon Southern 
Runcorn, England) was slurry packed with 5 u ODS Hypersil 
(Shandon Southern) using a Shandon column packer and 
fitted with a valve adaptor (Shandon Southern).
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Manual injections were made via a Rheodyne 7125 
injection valve (Scotlab Instrumentation Ltd., Law, by 
Carluke, Scotland).
Extraction Procedure Development
1. Choice of extraction solvents
One ml of serum spiked with 100 ug/1 ADR, ADRol,
ADRone and DAUN) was mixed with 1 ml of 10 mM phosphate- 
buffered saline (pH 7.8) (Shinozawa et al, 1980). The 
drug was extracted by shaking with 5 ml of mixture of 
chloroform : methanol (4:1 by volume) for 10 minutes. Due 
to emulsion formation, another 5 ml of organic-phase was 
added and shaken. After centrifugation, the upper 
aqueous layer was aspirated and 5 ml of the organic layer 
was transferred into a conical tube. The mixture was
evaporated to dryness at 50**C under a stream of nitrogen.
The residue was dissolved in 100 ul methanol and 20 ul 
was injected onto HPLC column.
A second series of experiments was carried out using 
dichloromethane: isopropanol (4:1 v;v).
2. The effect of pH on the recovery of ADR and its
metabolite
This experiment was carried out using 10 mM 
phosphate buffer or 10 mM phosphate-buffered saline over 
the pH range of 2-8.8. The extraction was carried out by 
using aqueous standard.
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3. Choice of Internal Standard
DAUN has been used as internal standard by most 
workers (Pierce and Jatlow, 1979; Baurain et al, 1979). 
It has a similar structure and similar physiochemical 
properties to ADR and has not been used clinically as 
adjuvant with ADR. In chromatography, DAUN is well 
resolved from ADR and its metabolites. It was therefore 
used as internal standard in these studies.
4. Optimised Extraction Procedure 
Serum and urine:
One ml of serum or urine was place in a Q + Q tube 
and mixed with 1 ml of O.OIM disodium hydrogen 
phosphate-buffered saline pH 7.8. To this was added 
10 ml of dichloromethane:isopropanol (4:1) containing 
200 ng of DAUN as internal standard. The mixture was 
shaken for 10 minutes in a lateral shaker (Griffin and 
George, L o n d o n , UK) and centrifuged for 10 minutes at 
2000 g . The aqueous layer was aspirated and the organic 
solvent was transferred to a conical tube and evaporated 
to dryness at 50"C under nitrogen.
The residue was dissolved in 50 ul of raobile-phase 
and 20 ul was injected onto the HPLC column. The ratio 
of analyte/internal standard peak areas were determined 
and compared with a calibration curve.
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Initial Development of Liquid Chromatography Method
A 10 cm X 4 mm ID column containing 5 u ODS Hypersil 
was first tried with detection of the red ADR at its peak 
wavelength of 490 nm.
1. The eluting solvents methanol and acetonitrile 
(CHgCN), alone, and a mixture of methanol and CH 3 CN 
in proportion of 1 : 1  were investigated.
2. In further experiments octanesulphonic acid, an 
ion-pair, was added to the methanol :CH3 CN (50:50) at 
a concentration of 1 mM.
3. The addition of water or buffers to the mobile-phase 
in order to increase the polarity was investigated.
In all these experiments a mixture of 5 ug/ml each of 
ADR, ADRone, ADRol and DAUN was injected.
Further detection experiments were carried out using 
a fluorescence detector with interference filters at 450 
and 550 nm for the excitation and emission wavelength 
respectively.
Further Development of the HPLC Method
1. The effect of increased solvent polarity 
A solvent consisting of CH3 CN : 10 mM phosphoric acid 
in proportion of 1:1 v:v was found to elute the ADR, 
metabolites and DAUN. Different proportions were used in 
order to determine the mobile-phase which yielded the 
highest resolution.
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2. The effects of anionic surfactant on k ' and
resolution
To the appropriate solvent CHgCNilO mM phosphoric 
acid (35:65 v:v) were added increasing amounts of one of 
the following anions: pentanesulphonic acid, hexane­
sulphonic acid, heptanesulphonic acid or octanesul phonic 
acid. The concentrations used were 0, 0.75, 1.5, 3, 4, 5 
or 6 mM.
Overnight washing with acetone was carried out 
between experiments to desorb the ionic surfactant from 
the reverse-phase packing materials.
Injection of the anthracycline mixture at the 
different ionic surfactant concentrations were made after 
several hours equilibration, and repeated until two 
successive results corresponded exactly, indicating that 
the column had achieved steady state.
3. The effects of cationic and neutral surfactants
on the separation
To the appropriate mobile-phase were added 
increasing amounts of cationic and neutral surfactants. 
The cationic surfactants used were dodecyltrimethyl- 
ammonium bromide and tetraethylammonium bromide. 
Polyoxyethylene lauryl ether (Brij) was used as neutral 
surfactant. The concentrations used were again
0.75-6 mM,
Linearity, recovery, precision, sensitivity and 
accuracy were calculated for each of the modifications of 
the method as follows:
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Linearity
Linearity was studied by injecting 20 ul of the 
mixture of A D R , ADRone and ADRol and DAUN (IS) in 
methanol over the concentration range 0 - 1 0  ug on column 
(0-500 mg/1 standard) (0-10“^M).
Recovery
Sera of known ADR concentration to which IS had been 
added ,were assayed and the result was compared with 
direct injected standard mixture in order to calculate 
the absolute recovery.
Precision
Serum and urine;
The precision was assessed by determining ADR, ADRol 
and ADRone in serum (n - 20) at two concentrations
100 u g / 1  and 500 u g / 1  (20 n g , 100 ng/column) (2 x lO'^p^ 
and 1 0 ”^M).
Accuracy
Since there is a possibility of interference by a 
number of drugs, especially anti-cancer drugs, in samples 
obtained from patients.The response of the chromato­
graphic method to directly injected aqueous solutions 
( 1 g / 1  ) of cyclophosphamide, dacarbazine, fluorouracil, 
vincristine, vindecine, vinblastine and cis-platinum, 
cytarabine, M T X , 7-OHMTX, DAMPA, trimethoprim, para­
cetamol and diazepam was checked. The last two were
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included since they are commonly prescribed to patients 
receiving anti-cancer drugs. The accuracy was determined 
from recovery studies.
Sensitivity
The sensitivity of detection of ADR and each 
metabolite was determined by finding the lowest 
concentration in serum which would give rise to a peak 
with a height = 2 x baseline noise level.
Application of the Method to Biological Specimens
1. Human biological fluids
Two patients were given 40 mg ADR as an IV infusion 
over 4 hours. Blood samples were drawn from one patient 
at 0, 1, 2, 3, 4, 5 and 18 hours after commencement of 
infusion and at 0, 1, 4, 5 and 7 hours from the other.
Urine samples were collected every 2 hours, from -2 
to 0 hours (start of infusion) 0-2 and 2-4 hours. One 12 
hour sample was collected after completion of the 
infusion. The plasma samples and the urines were kept at 
-20°C until analysed.
2. Bacterial broth
A variety of bacterial strains were grown in 
Mueller-Hinton broth. These strains used were: Citro- 
bacter Preundii, Klebsiella Pneumoniae, Pseudomonas 
Aeruginosa, Actinetobacter Calcoacetius Var Anitratrium, 
Escherichia Coli spp (E. Coli), Klebsiella spp and 
Pseudomonas spp. To the cultures in broth was added 
10~^M ADR and incubation continued for 24 hours. Blank
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samples were obtained from cultures containing no ADR. At 
the end of the incubation the bacteria were removed by 
centrifugation at 1 500 g to produce a clear supernatant 
solution which was stored at - 2 0  until analysed.
Method of Analysis
The HPLC method used to measure ADR and its 
metabolites as modified slightly as follows;
1j Human biological fluid
The mobile-phase used was acetonitrile: 0.01M 
phosphoric acid (containing 5 mM Brij) in proportions 
35 : 65 V : V .
2. Bacterial broth
The mobile-phase was acetonitrile;methanol:water 
containing (1 mM octanesulphonic acid) in proportions 
30:40:30, v;v;v.
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RESULTS
Extraction Procedure Development
1. Extraction with chloroform;methanol
This gave a low recovery for ADR (32%) and ADRol 
(60%), ADRone and DAUN were decomposed, two peaks 
appearing on the chromatogram as in Figure 38.
2. Extraction with dichloromethane: isopropanol 
This gave a high recovery, and no decomposition
occurred. This solvent was used in subsequent 
experiments.
3. Optimisation of extraction procedure
The effect of pH on the recovery of ADR, ADRol and 
ADRone extraction is shown in Figure 39 using DAUN as IS. 
From Figure 39 it can be seen that the most efficient 
extraction occurred at a pH of 7.8 using phosphate- 
buffered saline.
Development of Liquid Chromatography Method
1. ADR and its metabolites were unretained when eluted 
with methanol, acetonitrile alone and a mixture of 
both.
2. ADRone, ADRol, and ADR had the same k ' which was 
different from DAUN. This occurred when 1 mM 
octanesulphonic acid was used as ion-pair with 
methanol:acetonitrile ( 50:50).
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FIGURE 38 Chromatograms obtained from serum spiked with
ADR and metabolites (DAUN as internal standard) 
Extraction with Chloroform :Methanol,
ADRone and DAUN decomposed and appeared to be 
in two peaks.
Doxorubicin aglycon 
-# Doxorubiclnot 
-# Daunorubicin
Doxorubicin
100^
50
PH of the NagHPO^-Saline buffer
FIGURE 39 The effect of pH on the percentage recovery of ADR 
and its metabolites during extraction from serum.
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3. The chromatogram of ADR and its metabolites with 
DAUN using methanol : water :acetonitrile (OSA%) in 
proportions of 40:30:30 ( 1 mM) as a mobile-phase is 
shown in Figure 40, The capacity ratios (k'), 
resolution and h value are shown in Table 24.
Further Development of the HPLC Method
1. The effect of increased solvent polarity
The effect of increasing polarity (by decreasing the 
concentration of C H 3 CN in the final volume) on the 
retention time of ADR, ADRol, ADRone and DAUN is shown in 
Figure 41 , Increasing the polarity increased the 
retention time but not by the same ratio for each 
component, i.e. the resolution was affected. Figure 41 
shows the effect of increasing polarity on the resolution 
and indicates that the resolution between ADRone and 
ADRol decreased as the polarity increased.
The most efficient mobile-phase was found to be 
C H g C N : 10 mM phosphoric acid (35 :65 v ;v ), this gave the 
best resolution. However, the retention time for DAUN 
was unacceptably long at 13.3 minutes.
2. The effect of anionic surfactants on k* and 
resolution
Table 25 shows the effect of increasing alkyl chain 
length of the anion on the k* of ADRone, ADRol, ADR and 
DAUN. The k ' of ADRone alone was unaffected by 
increasing alkyl chain length.
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FIGURE 40 Chromatograms of ADR and metabolite standards with
DAUN as internai standard. The mobile-phase was 
Methanol:Acetonitrile:Water containing 1 mM octane- 
sulphonic Acid (40:30:30).
Peak identities are:
1 =s Doxorubicin aglycone (ADRone)
2 - Doxorubicinol (ADRol)
3 *= Doxorubicin (ADR)
4 - Daunorubicin (DAUN)
TABLE 24
The Capacity Ratio (k'), reduced plate height (h) 
and the resolution (Rs) for ADR and Metabolites with 
DAUN as Internal Standard using CH^CN;Methanol:Water 
containing 1 mM Octanesulphonic Acid in proportions 
30:40:30 as Mobile-Phase.
ADRone ADRol ADR DAUN
k' 1.22 6.8 8.6 14.6
41 8.6 7.5 7.09
Rs 8.5 2 4.9
c<D
£
c
0*VJ1
o Doxorubicin aglycon 
Doxorubicinol 
-« Doxorubicin 
Daunorubicin
20 -
18 -
16 -
14 -
1 2 -
10 -
50:50 35:65 30:7040:60
acetonitrile : phosphoric acid
FIGURE Al The effect of solvent polarity on the retention time
of Doxorubicin aglycon, Doxorubicinol, Doxorubicin 
and Daunorubicin.
TABLE 25
Effect of Sulphonic Acid Chain Length and Concentration on the 
k' of ADRone, ADRol, ADR and DAUN
Surfactant
Concentration ADRone ADRol ADR DAUN
Pentanesulphonic
acid
O ' 1.8 2.5 4.5 11
0.75 1.8 2,0 3.5 9
1.5 1.8 1.5 3.0 7.7
3.0 1.8 1.2 2.5 6.3
4.5 1.8 1.1 1.9 5.0
6.0 1.8 1.0 1.9 5.0
Hexanesulphonic
acid
O 1.8 2.5 4.5 11
0.75 1.8 2.0 2.4 8.7
1.5 1.8 1.6 2.9 7.4
3.0 1.8 1.3 2.5 6.0
4.5 1.8 1.1 2.2 5.6
6.0 1.8 1.0 2.0 5.0
Heptanesulphonic
acid
O 1.8 2.5 4.5 11
0.75 1.8 2.0 3.5 8.5
1.5 1.8 1.7 3.2 7.7
3.0 1.8 1.3 2.6 6.5
4.5 1.8 1.1 2.35 5.9
6.0 1.8 1.0 2.35 5.8
Octanesulphonic
acid
O 1.8 2.5 4.5 11
0.75 1.8 2.1 3.7 8.7
1.5 1.8 1.9 3.35 8.1
3.0 1.8 1.7 3.0 7.0
4.5 1.8 1.6 2.8 6.6
6.0 1.8 1.6 2.45 6.0
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Figure 42 shows the effect of increasing alkyl chain 
length of anion on the resolution between ADRol and 
ADRone,
Figure 43 shows the resolution between ADR and ADRol 
with the addition of sulphonic acids of different chain 
length to the eluant. 3 mM pentanesulphonic acid was 
found to give the best resolution in association with low 
k* valpes.
3. The effect of cationic and neutral surfactants
on separation
The effect of tetraethylammoniurn bromide, dodecyl- 
trimethylammonium bromide and Brij on the capacity ratios 
for ADRone, ADRol, ADR and DAUN is shown in Figure 44a, 
b ,and c respectively. It can be seen that the Brij 
gave the best resolution along with an acceptably low 
retention time for DAUN. The most satisfactory 
mobile-phase was thus determined as CH;)CN : 10 mM 
phosphoric acid (35:65) containing 6 mM Brij,
Linearity
At each stage of development the HPLC method was 
found to be linear over the range 0 - 1 0  ng on column 
sample weight.
Recovery
The absolute recoveries for ADR, ADRol and ADRone 
are shown in Tables 26, 27 and 28 for the method at
different stages of development. The recoveries relative 
to DAUN as IS were calculated to be 97.1+3.8% at all 
stages.
Resolution betw een Doxorubicinol and Doxorubicin aglycon
-a Pentanesulphonic acid
Hexanesulphonic acid
Heptanesulphonic acid
“O Octanesulphonic acid
+ 1-
0 -
R
—1 "
- 2
0.75 mM
FIGURE 42 The effect of different concentrations of anionic
surfactants on the resolution between Doxorubicinol 
and Doxorubicin aglycone. The area between the two 
dotted lines is that of incomplete resolution.
Resolution between Doxorubicin and Doxorubicinol
-# Pentanesulphonic acid
■o Hexanesulphonic acid
-# Heptanesulphonic acid
o  Octanesulphonic acid
4515075
m M
F IG U R E  43 The effect of different concentrations of anionic
surfactant on the resolution between Doxorubicin 
and Doxorubicinol.
•oDaunorubicin
•• Doxorubicin ol
10-
-A Doxorubicin aglycon
k'
4.5
Dodecyltrimethylammonium bromide CmM)
FIGURE 44a The effect of different concentrations of Dodecyl-
• trimethylammonium bromide on the k* of ADR and its 
metabolites and DAUN.
15- Do x o r u b ic in
-o Do x o r u b ic in o t
10-
k'
5-
1.5 4.530.75 C
T e t r a e  t h y la m m o n iu m  b r o m i d e  ( m M )
FIGURE 44b The effect of different concentrations of Tetraethyl- 
ammoniura bromide on the k' of ADR and its metabolites
and DAUN.
“® Oaunorublcin
-o  Doxorubicin 
~ A  Doxorublclnot 
-m Doxorubicin aglycon
10*
k'
7-
-o
2 -
1.50.75
Brii 35 (mM)
F IG U R E  44c The effect of Polyoxyethylene lauryl ether (Brij)
on the k* of ADR and its metabolites and DAUN.
TABLE 26
Absolute Recovery (n = 20) ADR and ADRol using Acetonitrile : Methanol': 
Water containing i niM Octanesulphonic acid in proportions 30:40:30 
as a mobile - p h a s e ____________________________________
Concentration
Compound Mass Unit____  Molar Unit Recovery
ADRol 10 ug/1 1.83 X  10~^ 90±5.3
ADR 10 ug/1 1.83 x lo"® 73±2.7
ADRol 100 ug/1 1.83 x lo"^ 95.1+2.4
ADR 100 ug/1 1.84 X  lo”  ^ 84.7+3.1
TABLE 27
Absolute Recovery (n - 20) of ADR and its Metabolite, using Aceto­
nitrile :0. OlM Phosphoric Acid containing 3 mM Pentanesulphonic Acid 
in proportions 3 5:65 as a Mobile-Phase_______________________________
Concentra tion
Compound Mass Unit____  Molar Unit Recovery
— "7
ADRone 100 ug/1 2.4 x 10 72.8±4.7
7
ADRol loo ug/1 1.83 x 10 87.5+7.7
ADR loo ug/1 1.84 x lo”  ^ 82.75+6.1
“ 6
ADRone 500 ug/1 1.2 x lO 74.5+2.46
ADRol 500 ug/1 9.16 x lo“  ^ 96.2+3.6
ADR 500 ug/1 9.19 x lo"^ 97.312.3
TABLE 28
Absolute Recovery (n - 20) ADR and its Metabolites using Acetonitrile 
O.01 Phosphoric Acid containing 6 mM Polyoxyethylene Lauryl Ether 
(Brij) in proportions 35:65 as a Mobile-Phase__________________________
Concentration
Compound Mass Unit____  Molar Unit Recovery
7
ADRone 100 ug/1 2.4 x 10 82.1±5.1
-7
ADRol 100 ug/1 1.83 x 10 92.2±4.7
ADR 100 ug/1 1.84 X  lo”^ 95.4±3.9
ADRone 500 ug/1 1.2 x 10 ^ 90.115.5
-1
ADRol 500 ug/1 9.16 x 10 92.414.8
ADR 500 ug/1 9.19 x lo” "^ 95.213.6
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Precision
The precision studies are summarised in Table 29. 
All coefficients of variation were below 10%.
Accuracy
None of the drugs examined interfered with the assay 
of ADR and its metabolites, nor were any endogenous peaks 
found which interfered with ADR and its metabolite peak 
Sensitivity
The limit of sensitivity of the three methods using 
plasma extracts was found to be 1.5 ug/1 (3 nmol/1). 
Application of the Method to Biological Specimens
1. Human biological fluids
(a) Serum
A chromatogram obtained from an extract of pre­
infusion serum is shown in Figure 45. Figure 46 shows 
the chromatogram obtained from an extract of serum from 
the same patient during treatment with 40 mg ADR by IV 
infusion over 4 hours. The chromatogram obtained from 
serum of the same patient, 1 hour after the end of IV 
infusion, is shown in Figure 47. The plasma profile of 
ADR and its metabolites during and after the IV infusion 
is shown in Figure 48,
(b) Urine
A chromatogram obtained from extracted urine from 
the same patient is shown in Figure 49.
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FIGURE 45 Chromatogram obtained from serum of a patient 
before an infusion of Doxorubicin.
4 «= DAUN (internal standard) .
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FI (SURE 46 Chromatogram obtained from the serum of a patient
treated with a 40 mg IV infusion of ADR over 4 
hours. The sample was drawn at 3 hours (during the 
infus ion).
Peak identities are as follows :
1 s= Doxorubicin aglycone (ADRone)
2 » Doxorubicinol (ADRol)
3 « Doxorubicin (ADR)
4 e= Daunorubicin (DAUN)
Ü « Unknown peak
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FK5URE 47 Chromatogram obtained from the serum of a patient
1 hour after stopping the infusion of ADR.
Peak identities as in Figure 46,
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FIGURK 48 Plasma profiles of ADR and its metabolites during
and after intravenous administration of ADR.
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FIGURE 49 Chromatograms obtained from extracts of urine 
from a patient treated with 40 mg ADR as IV 
infusion over 4 hours.
Peak identities as in Figure 46.
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The cumulative urinary excretion of ADR and ADRol 
from 0-28 hours is shown in Figure 50 for two patients. 
The total percentage of ADR excreted during 24 hours post 
infusion was about 6 % of the total dose infused,
2. Bacterial broth
A chromatogram obtained from extracted supernatant 
broths is shown in Figure 51, showing the presence of an 
uniden^tified peak in the ADR containing broth. This peak 
was found to a different extent in all cultures (Table 
30) and to a small extent (28%) in the broth incubated 
with ADR alone. It was not present in supernatant broth 
from cultures incubated in the absence of ADR. Although 
it has not been proven to be an ADR metabolite, it is 
highly sugges table that it is so, and its structure 
remains to be identified.
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FIGURE 50 Recovery of ADR and metabolites from urine during
and following ADR infusion. (Two patients)
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FIGURE 51 Chromatograms of ADR and unidentified peak 
found in:
A ~ Broth alone incubated with ADR 
B - Bacterial broth incubated with ADR 
Peak identities are:
U = Unidentified peak 
ADR = Doxorubicin
TABLE 30
The Percentage of Unidentified Peak present in Cultures of 
Different Strains of Gastrointestinal Bacteria isolated from 
Different Patients
Bacterial SPP
% Concentration of 
Unidentified Peak
Citrobacter Freundu 
Klebsiella Pneumoniae 
Pseudomonas Aeruginosa
Acinetobacter Calcoacetius var. Anitratrium 
Escherichia Coli (E. Coli)
E. Coli
Klebsiella SPP 
E. Coli 
E. Coli 
E. Coli
Pseudomonas SPP 
Pseudomonas Aeruginosa 
E. Coli
Klebsiella SPP 
E. Coli 
E. Coli
E. Coli (non-lactose fermenter)
E. Coli
Pseudomonas SPP
E. Coli
Broth
100
100
77
45
100
55
92
100
26
loo
40
83
100
22
100
loo
loo
100
50
26
28
* Unidentified Peak% =
height of Unidentified peak
height of ADR peak + height 
of unidentified peak
X loo
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DISCUSSION 
Method Development
ADRone and DAUN were decomposed by extraction with 
chloroform : methanol while dichloromethane :isopropanol 
extraction yielded a good recovery with no decomposition. 
This suggests that impurities in the chloroform are the 
most likely cause. The dichloromethane: isopropanol was 
found to be an acceptable solvent for extraction. This 
finding is in disagreement with Baurain et al (1979), 
Strauss et al ( 1980 ) and Shinozawa et al ( 1 980 ) who all 
used chloroform ; methanol as extraction solvent. From 
Figure 39 it can be seen that the recoveries for ADR and 
its metabolite with DAUN were excellent at pH 7.8 using 
phosphate buffered saline although the extraction 
efficiency was acceptable over a wide pH range (2-8.8).
The earlier method gave good resolution but showed a 
high retention time for DAUN. In addition the capacity 
ratio of ADRone was low at 1.22 and the peak co-eluted 
with endogenous components of plasma and urine.
When CHgCN : phosphoric acid was used as mobile-phase 
ADR, its metabolites, and DAUN eluted from an ODS column 
with good resolution but with unacceptably high retention 
times.
This method was found to have acceptable 
sensitivity, accuracy, recovery and precision with the 
added advantage of fast pre-sample work up.
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At a pH of 2,2, the major ionisation of the
anthracyclines would appear to reside in the amino 
grouping of the sugar moeity which would be in the form 
of NHg*^. The fact that the one metabolite which lacks 
this ionising grouping (ADRone) is unaffected by any of 
the surfactants, supports the view that any other
ionisations on the tricyclic ring are insignificant in
this cljiromatographic system.
The results obtained using the sulphonic acids
exclude the possibility that ion-pairing is the only 
mechanism in force, since formation of the less polar 
ion-pair would lead to an increased k ' for the three 
ionised species. This fact suggested that in this system 
the retention of the analytes is due not to affinity for 
the non-polar Cig chains but for free silanol groups 
which may carry a negative charge. The effect of the 
sulphonic acids may therefore be suppression of the 
ionisation of the weakly ionised silanol groups by 
competition for protons. The effect on k* of surfactant 
alkyl chain length may reflect the effects of polarity, 
increasing concentration also decreasing k'; since the 
proposed ion-exchange mechanism would be expected to be 
saturable, it is likely that a combination of suppression 
of ion-pair sites and modification of stationary-phase 
polarity is occurring.
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The similar effects exhibited by the cationic 
surfactant molecules can be explained by competition 
between these positive charged ions and the cationic 
anthracycl ines for the OH" groupings on uncapped silanol 
groups.
The effect of the non- ionised Brij is unrelated to 
charge and is a less strong effect, probably due to the 
effect of the detergent on either solvent viscosity, 
although there were no discernable pressure changes, or 
surface tension effects at the interface between the 
solvent and the surface of the packing material. It may 
be that such surfactant effects also make some 
contribution to the reduction in k ' resulting from the 
use of the cationic and anionic detergents.
In summary, an investigation into the effect of 
ion-pairing agents on the retention of anthracycline 
molecules on a reverse-phase column (Hypersi1 ODS 5 u) 
has revealed that the mechanism is not purely 
reverse-phase but may contain an element of ion-exchange 
chromatography involving uncapped silanol groups although 
this packing is claimed to have 'capped* silanol groups. 
An acceptable analytical method for the determination of 
anthracyclines at pH 2.2 using a non-ionic detergent has 
been developed using this packing material, but further 
studies particularly on other reverse-phase materials 
should be carried out to confirm this explanation.
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Human Biological Fluids
The chromatogram obtained from the serum pre­
infusion shows no interfering endogenous peaks. The 
sensitivity of the assay used was sufficient to detect 
less than 3 ng/column of the ADR metabolites. The 
unidentified peak found in each of the subsequent samples 
was either an impurity of the ADR pharmaceutical 
preparation (Barth and Conner, 1977) or one of the 8 
metabolites which were detected by Andrews et al (1980). 
The height of the unidentified peak was less in Figure 47 
than Figure 46 which suggests that it is most probably an 
ADR impurity.
The formation of the active metabolite (ADRol) is 
shown clearly in Figure 48. The concentration of ADRol 
was greater than that of ADR at 20 hours after the start 
of the infusion. The concentration of ADRone was also 
greater than that of ADR at 20 hours post infusion. 
ADRone has an almost flat elimination curve which 
indicates the difficulty in the excretion of this 
non-polar metabolite. The low total renal excretion 
( ^ 6 %) obtained from both patients suggests that the 
tissue pool for ADR is large, and that non-renal routes 
of excretion may well predominate.
The data obtained in this study are insufficient for 
pharmacokinetic calculations but are good enough to show 
that the method described can be applied to human
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biological fluids and offer a method of studying both ADR 
and its two major metabolites In order to further 
elucidate the way in which this drug is handled in man. 
Bacterial Broth
The studies using bacteria encountered one of the 
problems which have given difficulties to most others who 
have studied ADR metabolism, namely the breakdown of this 
rather^ unstable molecule during incubations and/or 
analysis.
ADR incubated in nutrient broth gave rise to a 
product which was present consistently at a peak height 
of 28% relative to that of the remaining ADR.
Incubation of ADR in broth in the presence of 
bacteria gave rise to widely different ratios, but no 
other peaks in the chromatogram.
Table 30 shows that within the limits of 
experimental error, 8 species gave rise to a pattern 
similar to that of the broth alone i.e. a 'metabolite' 
peak of relative height 22-50%. Ten species produced a 
metabolite peak considerably greater with consequent 
reduction in the amount of ADR recovery.
This in itself does not prove any bacterial 
metabolism, since the degradation of ADR may be related 
to the other factors such as alteration in pH or 
catalysis of breakdown by adsorption to bacterial cell 
walls.
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These studies therefore show only that neither of 
the known in vivo metabolites which it was possible to 
measure quantitatively, were produced in vitro by a 
variety of bacterial strains isolated from human gut.
The fact that the peak was not detected in vivo also 
suggests that there is no detectable involvement of 
gastrointestinal bacteria in ADR metabolism in man, any 
metabolites which may be produced being excreted in the 
faeces rather than being absorbed.
The conclusion from these early studies are that the 
method developed is capable of measuring ADR and at least 
two of its metabolites in plasma and urine following the 
administration of doses in the range currently regarded 
as optimal. It remains to be seen whether the regular 
measurement of these analytes could lead to improvements 
either in the efficiency of treatment or in avoidance of 
toxicity. The bacterial studies indicate that it is 
unlikely that gastrointestinal bacteria contribute 
significantly to the variations in the effect of ADR in 
man.
CHAPTER 8
GENERAL DISCUSSION
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GENERAL DISCUSSION
Methotrexate
The assay developed for MTX and its metabolites has 
several advantages over other currently available 
m e t h o d s . MTX is labile at alkaline pH, thus ion
suppression with alkali to allow liquid/liquid extraction 
is an unattractive approach due to the losses that may be 
incurred. Other workers have used protein précipitants 
(Nelson et al, 1973; Howell et al, 1980), but the studies 
conducted in this thesis indicate that the high losses 
and potential for interference make such assays sub- 
optimal. Donehower et al (1979) used a liquid/solid 
extraction. By refining and optimising this technique it 
has proved possible to obtain reproduc ibly high
recoveries of MTX and its important Phase I metabolites; 
this has ensured the assay is robust in use and is very 
sensitive for all these components. It proved possible 
to inject urine directly onto the HPLC column, this 
ensured complete recovery whereas Donehower et al (1979) 
suffered losses of MTX and metabolites using a
liquid/solid extraction due to urinary salt competition 
with the analytes and the ion-exchanger.
The use of an ion-pairing agent in the HPLC eluant 
has afforded excellent chromatographic efficiency and 
effective resolution of MTX and its metabolites.
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including the Polyglutamates MTXG-j and MTXGg. The use of 
phosphoric acid instead of a buffer removes the problem 
of salt crystallisation.
Using this chromatographic system and using heat 
precipitation the HPLC method was used to monitor liver 
homogenate synthesis of the 7-hydroxylated products of 
MTX and DAMPA. The identity of the 7-OHDAMPA product was 
confirmed by NMR and EI/MS, unfortunately it has proved 
impossible to obtain a definitive identification of the 
peak found in clinical samples that has a k ' identical to 
7-OHDAMPA. However, there is some evidence to support 
the view that this is also 7-OHDAMPA; the UV spectrum of 
the two peaks were superimposable, also the peak is only 
observed in urine samples containing DAMPA, This study 
also supports the view that 7-OHDAMPA in vivo is a result 
of hepatic hydroxylation of DAMPA rather than 
deglutamation of 7-OHMTX which in turn adds further 
evidence against DAMPA being a product of enterobacterial 
metabolism as proposed by Donehower et a l (1979). These 
findings and the plasma DAMPA concentration time curve 
tend to confirm the report of Chatterji et al (1978) that 
the source of DAMPA is the IV infusion.
The clinical significance of DAMPA and 7-OHDAMPA is 
unknown although their concentrations are two and three 
orders of magnitude respectively less than MTX, However, 
their solubilities in acid urine are markedly less than
131
for MTX (Donehower 1980) and they may contribute to 
nephrotoxicity, especially following prolonged admini­
stration of MTX.
The studies on high and low-dose MTX showed great 
variation in the pharmacokinetics within the population. 
Intra-individual variation in clearance was remarkably 
constant in the low-dose s t u d y , in the high-dose study 
this was not the case and may be due to the continuation 
of the disease process and adverse effects on the kidney.
The source of variation in bioavailability in the 
low-dose study has been ascribed to intra-individual 
variation in hepatic clearance on MTX presented via the 
portal vein, the so-called 'first pass' effect. Whether 
this is the result of differences in hepatic blood flow, 
enzyme induction by e.g. smoking or variation in gut 
absorption cannot be ascertained; this aspect merits 
further investigation.
It is of interest that in the high-dose kinetics 
there was no appreciable change in hepatic clearance of 
MTX on consecutive doses, the changes being mainly renal. 
There was a slight change in MTX AUC but a much more 
marked change in 7-OHMTX AUC and clearance. In view of 
the constancy of MTX hepatic clearance this change cannot 
be ascribed to hepatic enzyme induction and is therefore 
the result of an accumulation of 7-OHMTX which is not
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being excreted renally; the impaired mechanism may be pH 
dependent solubility in the urine but this is unlikely, 
it is more probable that it is the combination of reduced 
filtration, and diminished secretion.
The investigations of MTX metabolism of bacterial 
and human cell lines in vitro provided evidence of some 
metabolic activity but there was no conclusive evidence 
as to whether such activity affected the toxicity of MTX 
to cells.
Anthracyclines
The use of fluorimetric HPLC for anthracycline drugs 
has resulted in the publication of a number of sensitive 
assays applicable to clinical material (Baurain et al, 
1979; Andrews et al, 1979; Strauss et al 1980 ), Initial 
work showed that although the required separations could 
be achieved ADRone was poorly resolved from other 
components; it was noted that no other published method 
used an 'ion-pair' reagent. The experiments subsequently 
conducted resulted in the description of a novel ionic 
surfactant - solute - silanol interaction, and finally 
resulted in the use of an non-ionic surfactant. The 
principles described may be applied to many other 
analytes. The reduction in analysis times and enhanced 
resolution resulted in a highly sensitive assay.
The assay was applied to the study of the in vivo 
metabolism of ADR and the in vitro metabolism by 
bacteria. The former indicated the utility of the method
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but lack of clinical material meant that studies on the 
role of metabolites in toxicity have yet to be fully 
developed. The in vitro work indicated that certain 
cells can metabolise ADR but the relevance of this to ADR 
cellular toxicity requires further investigation.
In conclusion the development and application of 
sensitive, accurate and precise assays of two anti-cancer 
agents, MTX and ADR, and their metabolites have enabled 
studies at high and low doses to be performed. With such 
assays it would be possible to monitor therapy and assess 
the effect of not only the parent drug but its 
metabolites. As such drugs have very low therapeutic 
indexes and are often used consecutively or concurrently 
there are very likely to be changes in their pharmaco­
kinetics. Such changes could be of great clinical 
significance and could add to our ability to optimise 
chemotherapeutic regimes in cancer treatment. The assays 
described are capable of meeting such a challenge.
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